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                                              ABSTRACT 
 
Evaluation of the anticonvulsant activity of Elytropappus rhinocerotis (L.f) Less. 
 
O.IYAMU 
M.Pharm thesis, Discipline of Pharmacology, School of Pharmacy, University of the Western 
Cape. 
Epilepsy is a worldwide neurological disorder which is also prevalent in South Africa. Herbal 
medicines, besides orthodox medicines, have been used from time immemorial for the treatment 
of epilepsy even though, generally, there is want of scientific evidence to substantiate their 
effectiveness.  
People with epilepsy have used different types of plants and herbs now known as herbal 
therapies over thousands of years although no clinical benefit is implied by this term.  Moreover, 
the use of traditional medicine to treat CNS disorders such as epilepsy in South Africa still lacks 
a lot of scientific data although a study that was conducted in the Western Cape Province of 
South Africa revealed that the people in the Bredasdorp community use Elytropappus 
rhinocerotis to treat convulsions.  
Hence, the main objective of this current study was to evaluate the anticonvulsant activity of 
Elytropappus rhinocerotis. Other objectives were: to determine the safety profile by performing 
acute toxicity test; determination of chemical components through phytochemical analysis and 
the determination of HPLC fingerprint of the plant sample. 
E. rhinocerotis belongs to the family, Asteraceae. It is an erect bushy shrub which grows up to 1 
to 2m in height; with minute, grayish-green leave. It is known in Afrikaans as “renosterbos”. 
To realize the objectives of this study, the dried leaves of E. rhinocerotis were milled into fine 
powder. The dried powder was then extracted in methanol. The resultant filtrate was evaporated 
to a semi-solid extract which was then freeze-dried to obtain a dried leaf methanol plant extract. 
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The anticonvulsant effects of the methanol leaf extract of E. rhinocerotis was studied by 
chemical induction of seizure in experimental mice using standard convulsant agents such as, 
pentylenetetrazole (PTZ), bicuculline, picrotoxin, N-methyl-DL-aspartic acid and strychnine.  
All of the experimental mice manifested tonic convulsions induced by Pentylenetetrazole (PTZ) 
(100 mg/kg, i.p), bicuculline (30 mg/kg, i.p), picrotoxin (20 mg/k, i.p), N-methyl-DL-aspartic 
acid (NMDLA) (500 mg/kg, i.p) or strychnine (2 mg/kg, i.p).  Tonic convulsions induced in 
experimental mice by PTZ, bicuculline, picrotoxin or strychnine was significantly antagonized 
by leaf methanol extract of E.rhinocerotis (200 and 400 mg/kg, i.p), muscimol (2 mg/kg, i.p), 
phenobarbitone (12 mg/kg, i.p) or diazepam (0.5 mg/kg, i.p). The tonic convulsions induced in 
mice by NMDLA (500 mg/kg, i.p) was significantly antagonized by leaf methanol extract of 
E.rhinocerotis (400 mg/kg, i.p).  Strychnine induced tonic convulsions in mice was significantly 
antagonized by leaf methanol extract of E.rhinocerotis (400 mg/kg, i.p) and phenobarbitone (12 
mg/kg, i.p). Phenytoin had no effect on tonic convulsions induced by NMDLA, Strychnine, 
picrotoxin, PTZ or bicuculline. Diazepam also had no effect on tonic convulsions induced by 
NMDLA and strychnine. Tonic convulsions induced by NMDLA were not significantly 
antagonized by phenobarbitone. 
Oral doses of 100-4000 mg/kg of E. rhinocerotis were found to be non-toxic in experimental 
mice. No signs of acute toxicity or death were observed. The LD50 value obtained for E. 
rhinocerotis may be greater than 4000 mg/kg. 
In conclusion, the results obtained from this study showed that the methanol leaf extract of  E. 
rhinocerotis possess anticonvulsant activities. The mechanism of the anticonvulsant effect of 
E.rhinocerotis may be through involvement in the gamma aminobutyric acid (GABA), glutamate 
and glycine systems. Since E. rhinocerotis significantly delayed the onset of tonic convulsions 
induced by NMDLA and strychnine, the mechanism of the anticonvulsant activity of the plant 
may not be specific. The phytochemical analysis showed the leaves of E. rhinocerotis contain 
some chemical compounds such as; alkaloids, saponins, flavonoids, tannins, cardiac glycosides 
and triterpene steroids. The HPLC fingerprint of the leaf methanol extract of Elytropappus 
rhinocerotis showed distinct peaks at the following retention times, 4.227, 5.030, 7.698, 12.810, 
13.306, 15.333 and 18.563 minutes. 
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                                                     CHAPTER 1  
                                                INTRODUCTION 
Epilepsy is a worldwide neurological disorder which is characterized by recurrent seizures and it 
is also prevalent in South Africa. It is associated with episodes of altered behavior and/or 
consciousness, which can take many forms, but occurs from an abnormal electrical paroxysmal 
discharge in cerebral neurons (Cull and Goldstein, 1997). The type of epileptic seizures such as 
toni-clonic seizures also known as grand mal seizures, typical absence seizures, and myoclonic 
seizure depend on the part of the brain affected.  Epilepsy is extremely common, and has been 
presumed to be as a result of the massive interconnected organization the brain has. The 
prevalence of epilepsy worldwide reaches 1% and it is said that 10% of the population will have 
an epileptic seizure at some time but only 5% of these are febrile seizures of childhood (Zeman 
et al., 2012). It often starts in childhood and old age, less often in early/mid-adulthood. Its 
prognosis depends upon its cause, but about two-thirds of people who develop epilepsy stop 
having seizures either spontaneously or  treatment. Causes of epilepsy varies from genetic 
predisposition as shown by recent studies that some single gene mutations have epilepsy as their 
main manifestation, abnormalities of brain development, brain infections such as meningitis and 
encephalitis, head trauma, stroke, dementia (Zeman et al., 2012). Another known cause of 
epilepsy is as a result of imbalance in the GABAergic system which is the major inhibitory 
neurotransmitter in the mammalian central nervous system (CNS). Gamma-aminobutyric acid 
(GABA) exerts its physiological effects by binding to three different receptor types in the 
neuronal membrane; GABAA, GABAB and GABAC receptors. The GABAA receptor is mainly 
involved in epilepsy. It has a binding sites for compounds such as benzodiazepines that 
allosterically modify the chloride channel gating of GABA (Jäger et al.,  2005).   
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In adult onset epilepsy, the cause remains unknown in about 50% of the cases. Epilepsy is not 
easily diagnosed. It depends on a vivid description of the events occurring in seizures, both from 
the victim’s perspective and by an eye witness. Several tests can be helpful in making a 
diagnosis, but it may remain unclear despite these. Standard investigations include EEG (Zeman 
et al., 2012). 
Medicinal plants and their derived products have been a key source of traditional medicine (TM) 
from time immemorial worldwide prior to the synthetic era. Around 80% of all medicines were 
obtained from natural products mainly from medicinal plants and play an important role in the 
healthcare systems of developing countries (Singh et al., 2014) 
According to the World Health Organization (WHO), more than 80% of the world population 
relies on traditional healthcare practices to cater for their healthcare needs. TM comprises of the 
knowledge, beliefs, skills and lifestyle practices including the use of plants, animals, spiritual 
therapies, exercises, mineral based medicines and experiences that are practised by different 
cultures to improve and maintain the healthcare needs of various communities. Although, as 
important as TM is, some countries still underestimate its importance (WHO, 2005; WHO, 
2015).  
Sometimes, the terms complementary and alternative medicine are used interchangeably with 
TM in some countries. Different countries have their various ways of practicing TM as the 
practices depend on the cultures,  long history and tradition passed on from generation to 
generation, perceptions, personal belief and attitudes which have all in one way or another 
proven the safety, efficacy and reliability of TM. The use of TM is rapidly spreading in most 
industrialized countries because its popularity has been maintained in developing countries and 
http://etd.uwc.ac.za
 
 
3 
 
the market growth rate for TM worldwide is increasing and steady (WHO, 2005). It has been 
observed that there has been a continued demand for TM around the world since WHO 
developed its first global strategy, Many countries now use TM to treat chronic diseases and 
other ailments such as cancer, diarrhoea, malaria, pain and fever, arthritis, anxiety, physical and 
mental disorders. It is also used in public health promotion and prevention of most diseases and 
the reasons why most countries prefer the use of TM is because of its cost-effectiveness, easy to 
use and reliability (WHO, 2005; Kabatende, 2005). 
Although, TM is recognized in so many countries, it is still not officially recognized in most 
countries and it is still lacking enough scientific evidence from research to prove its safety and 
efficacy. Therefore, more and improved research is needed but it is vital that when conducting 
these researches, the long history, tradition, practices, experience and knowledge of TM should 
be taken into considerations. This then leads to the support of training and education needed for 
the research of TM. Even though, there  have been some evidence so far from research that has 
proven the safety and efficacy of some of the TMs, the results are still not sufficient to meet the 
criteria that enables a world wide support because of the health care policies of some countries 
and also some research methodologies used for evaluating and assessing  TM are lacking. Most 
countries have been able to provide some evidence which have been published and not published 
so this requires an improvement in the quality of research and more scientific evidence to prove 
the safety and efficacy of TM (WHO, 2015). 
In order, to improve the quality of research in TM and to provide  more proof for safety and 
efficacy, some guidelines and strategies were created by the World Health Organization (WHO) 
to assist with the research process, methodologies used during research to have enough assurance 
and guarantee the safety and efficacy of herbal medicines  and traditional procedure-based 
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therapies and avoidance of obstacles that might arise when developing and during the application 
of TM. However, this has been difficult for research organizations and scientists to adhere to. 
The purpose of the guidelines outlined by WHO were  basically to help improve and promote the 
proper use and development of  TM as previously mentioned, so it is very crucial for researchers, 
healthcare providers and TM practitioners to always refer to these guidelines. The guidelines also 
suggest botanical verification (i. e. Identification of the plant species as a first stage in quality 
assurance, the safety and efficacy of herbal medicine which should be practiced in every country 
(WHO, 2015). 
Safety and efficacy issues remain a huge concern when it comes to the use and research of TM as 
the inappropriate, unregulated use and practices of TM can be detrimental and pose a big threat 
to the world. Some evidence have been brought to light concerning the safety issues of some 
herbs; for instance, the case of the Chinese herb “Ma Huang” also known as Ephedra which was 
known to be safe for the treatment of respiratory congestion and was later found out to be 
marketed as a product to aid diet and had fatal effects such as death, stroke and cardiac arrest in 
the US. Another guideline was then created by WHO to assist countries to develop adequate 
patent laws under approved international standards to protect the knowledge and biodiversity of 
TM, to create stronger evidence of safety and efficacy, to enable a more cost-effective and 
affordable TM and the documentation of remedies used (WHO, 2015).  
South Africa is a diverse nation with many tribes and traditional practices which are sometimes 
connected to the practice of traditional medicine. The Zulu tribe is most commonly associated 
with traditional healers which they refer to as, “inyangas”, or herbalists and “isangomas”, or 
diviners (Kabatende, 2005). The knowledge of herbs is mostly acquired by the elderly folks in 
rural areas mostly because of their passion for plants and herbs and the knowledge gained from 
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experience that has been passed on from generation to generation. There are also the spiritual 
healers who treat CNS disorders and other related problems. For most people in the rural areas, 
the use of plants have been known to them as the only source of different remedies and the only 
cure and treatment that they trust to be effective to treat all kinds of ailments from generation to 
generation (Van wyk et al., 2000; Kabatende, 2005). 
In most African countries including South Africa, TM is a significant part of the culture of the 
people that indulge in its practice. Hence, it is associated with their beliefs and attitudes. The 
quality of the plants use in TM can be affected by various factors such as; environmental 
conditions, species variation, the time of harvesting, storage and processing. These factors can 
make the plant’s medicinal use less potent and unsafe. Therefore, it is very essential for the 
quality control (QC) of plant extracts of any research to involve; safety, efficacy and effective 
therapy. Although, the QC of medicinal plants is a very complex task because medicinal plants 
comprise of various compounds that are not easily identified (Kabatende, 2005). Some scientific 
researches have shown that some active compounds including flavonoids, terpenes and some 
derivatives of caffeic acid  are presents in medicinal plants (Mauri et al., 2000). Some studies 
have also shown that the basis of any classification of medicinal plant from data interpretation 
such as potential therapeutic use of the plant extract is from a complete study of the 
pharmacological profile of the plant extracts (Atta and Alkofahi, 1998; De Sarro et al., 2000; 
Rabbani et al., 2003). 
People with epilepsy have used different types of plants and herbs now known as herbal 
therapies over thousands of years although no clinical benefit is implied by this term (Schachter,  
2009).  Moreover, the use of TM to treat CNS disorders such as epilepsy in South Africa still 
lacks a lot of scientific data although a study that was conducted in the Western Cape province of 
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South Africa, revealed that the people in the Bredasdorp community use Elytropappus 
rhinocerotis to treat convulsions. Hence, the main objective of this current study was to evaluate 
the anticonvulsant activity of Elytropappus rhinocerotis  (Thring and Weitz, 2005). 
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CHAPTER 2  
                                     LITERATURE REVIEW 
2.1 INTRODUCTION 
2.1.1. Overview on traditional medicines. 
 The interest in the knowledge of traditional medicines is rapidly increasing and gaining a 
significant amount of recognition worldwide and is included in the development of policies and 
scientific literatures. TM plays a significant role in the health of majority of the people in Africa. 
Medicinal plants are quickly regaining their famous position that they were known for in past 
eras in modern medicines and has always held in most part of the world which has made the use 
of the plants become an important part of the lives of the people in Africa as well as in the 
western world, Asia and other undeveloped parts of the world despite the fact that modern 
medicine and pharmaceutical research have gained a lot of advancement. In the Venda area of 
South Africa, for instance, there are about 200-700 people attended to a traditional medicine 
practitioner, while a university trained medical doctor has about 1639 people assigned to 
him/her. African traditional medicine has its own methodology, the fact that certain aspects of it 
do not follow/ are not on the same level of knowledge in science should not cause much 
limitations. Basically, it has been known to treat and cure many ailments which were all not as a 
result of chance, but based on years of experience, teaching and observations passed on from 
generation to generation. The Pharmacopoeia of the African medicinal healer comprises of 
treatment and cures for various ailment and diseases that cause affliction to people such as; 
dysentery, snake bite, skin conditions, whooping cough, diabetes, pain,  inflammation and so on. 
Modern medical practitioners have indicated that medicinal plants can cure some difficult 
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diseases that affect humans such as cancers and various immune deficiency disorders. The World 
Health Organization (WHO) has described TM as one of the surest means to gain total healthcare 
coverage of the world’s population. The attention currently received by TM from various 
governments to allow for a widespread healthcare application, has lead to an increase in research, 
funding and development of programmes in several developing countries despite the hindrance it 
has received over the past years (Iwu, 1993; Cunningham, 1997; Li, 2002; Kabatende, 2005). 
In the past, plants were discovered to have medicinal values based on traditional practices and 
accidental discoveries without scientific proofs. Recently, researches conducted on medicinal 
plants have generated some proof and a significant amount of information about the biologically 
active chemical components that are responsible for the medicinal claims. Almost 50% of 
medicines on the market are made from natural fundamental materials. A lot of the active 
ingredients in medicinal plants cannot be prepared synthetically yet, which will likely increase 
the market demand for medicinal plants which have potenial in healthcare improvement. High 
cost of modern medicines and pharmaceutical services in the developing world has created room 
for medicinal plants to be used continuously in medical practice (Iwu, 1993; Li, 2002). 
Until recently, the people who have mainly used medicinal plants in Africa have been  the local 
people in the communities. The field has now attracted a number of different researchers who 
have discovered the value of traditional healing and this has resulted in more interests in 
different areas of research of TM. Some of the aspects of medicinal plants that researches were 
first conducted on were; ethno-botany which gave researchers the insight for new drug 
discoveries based on medicinal plants uses; phytochemistry and chemistry of natural products, 
organic synthesis and the usefulness of medicinal plants. Some literatures have considered 
African medicinal plants from two points of view; firstly, as sources of biologically active 
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compounds and secondly, as elements in the complex equation of healing. One might think that 
the two aspects are different but a closer inquiry will show a similarity in the two modes of 
medicinal plant utilization in African traditional medicine (Iwu, 1993; Kabatende, 2005). 
The first consideration of treatment that comes to the mind of many Africans when they are 
ill/sick, especially the under-privileged in both rural and urban areas, is usually to use medicinal 
herbs. Even up to date, there are still many rural communities in Africa that still rely on 
traditional herbal medicines as their major and first point of healthcare source (Kabatende, 
2005). Hence, it is difficult not to accept and doubt the efficacy of herbal remedy within the 
African society (Sofowora, 1982). The importance of  using TM and the use of medicinal plants 
as a strategy for healthcare delivery have long been recognized by community workers in poor 
urban and rural areas which has allowed the communities to accept the safety and efficacy of TM 
but also to recognize the fact that the use of TM needs to be scientifically validated. The use of 
herbal medicines in communities has resulted not only in economic benefits and accessibility to 
much needed remedies. The use of TM has somehow, partially freed people from dependence on 
commercial drugs and has shown that the community has the ability to use and develop local 
plant resources to solve their healthcare problems which has led to their trust in the efficacy of 
herbal medicines. In many areas, especially the rural areas, the accessibility and availability of 
medicinal herbs have been able to offer people the use of safe and effective products to prevent 
and treat illness through self-medication. Some of such plants have been shown to be useful in 
modern medicine as well (Tomlinson and Akerele, 1998).   
However, some literature has suggested that it is very important for the traditional medical 
system to remain distinct and should not be consumed by modern medicine. The system should 
be allowed to complement the modern medical system by accepting its complexity furthermore, 
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the promotion of the herbal medicines that have been proven to be safe and effective (i.e. 
scientifically) should be encouraged at all times and in every sector of the community 
(Tomlinson and Akerele, 1998). 
South Africa has a rich cultural diversity which is reflected in the various ways in which 
medicine is practised presently in different parts of the nation (Kabatende, 2005). The use of 
traditional medicine is been referred to as phytotherapy by Biomedical literature. Traditional 
medicines and traditional healers form part of a broader field of study classified by medical 
anthropologist as ethnomedicine. Traditional medicine is usually associated with  herbal 
remedies and sort advice from the sangomas, which makes the role of the traditional healers 
important and considerable in developing the healthcare system in South Africa (Campaign and 
Richter, 2003). Traditional medicine is a comprehensive term that does not just refer to 
traditional medicine systems such as traditional Chinese medicine, but also Indian ayurveda and 
Arabic unani medicine, and also to other various forms of indigenous medicine. TM has been 
described by WHO as a system of medicine that is based on past experience and cultural beliefs 
and practices passed on from generation to generation, verbally or in writing, and traditional 
medicine includes diverse health practices, approaches, knowledge and beliefs incorporating 
plant, animal and/or mineral based medicines, spiritual therapies, manual techniques and 
exercises applied alone or in combination to maintain well-being, as well as to treat, diagnose or 
prevent illness. A deeper look into the concept shows that TM also include mystical and magical 
rituals, that is other kinds of treatment which may not be explained by modern medicine 
(Sofowora, 1982; Van Wyk et al., 2000; Bienvenu et al., 2002; Tabuti et al., 2003; Kabatende, 
2005; WHO, 2015). 
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A traditional healer is referred to as a person who is known by the community to which he or she 
belongs to be competent to provide healthcare. They are involved in diagnosing usually through 
spiritual means and  choosing and applying relevant remedies for the diagnosed condition. In 
most cases, the roots, leaves, barks or flowers of the plant are used as the compositions of the 
treatments (Richter, 2003; Kabatende, 2005; Reid et al., 2005). 
Although, a lot of research has been carried out about the constituents and biological activity of 
African medicinal plants and the scientific proof documented and published about these plants, 
some societies are still neglecting and have not fully accepted the development of therapeutic 
agents from African medicinal plants. Some studies have shown that the African continent is 
experiencing a  rapid loss of the natural habitat of some of the plants due to anthropogenic 
activities which have helped to increase the research and documentation of the  medicinal uses, 
the constituents and pharmacological activity of African plants (Iwu, 1993). Over the years, 
nature has been a source of medicinal agents, and an impressive number of modern day drugs 
have been isolated from natural sources, many based on their use in traditional medicine. These 
plant-based traditional medicine systems play a significant role in healthcare, with a huge 
amount of the world’s population relying mainly on traditional medicine for their primary health 
care need. People in the local rural areas and some parts of the urban community use a wide 
range of plants therapeutically to maintain their health. Hence, there is a great promise for new 
drug discoveries based on traditional plant uses (Lewis and Elvin-Lewis, 2003).  
 
 
 
http://etd.uwc.ac.za
 
 
12 
 
2.1.2. Advantages and Disadvantages of Traditional Medicine 
Some reports have revealed that the Western Cape Province of South Africa is enriched with a 
huge diversity of plants species which are used for treatment of different ailments due to their 
medicinal properties. These plants include Elytropappus rhinocerotis that is used for the 
treatment of epilepsy and other conditions such as  fever, bladder and kidney infections in some 
Western Cape communities (Van wyk et al., 2000; Thring and Weitz, 2006). 
Although, there have been a lot of reports and researches that have revealed the possible uses of 
traditional medicines and there is a continuous increase in traditional medicine awareness, many 
of the herbs are still untested. Their uses are not regulated and monitored which may lead to a 
high risk of harm as a result of lack of knowledge about their possible side effects. This limits 
the promotion of their rational use and makes it more difficult to identify the safest and most 
effective therapies (WHO, 2001; Kabatende, 2005). Medicinal plants/traditional medicines thus 
have some disadvantages which include; 
 The lack of scientific proof of their efficacy and toxicological profile (Sofowora, 1982). 
 Limited information in literatures regarding the proper usage of herbal medicines such as 
correct dosage, route of administration, frequency and when to use the herbs, possible 
side effects, drug and disease interaction ( Li, 2002). 
 Some medicinal plants are infested by some pests and pathogenic bacteria which can 
cause some diseases to the individual taking them if not properly cultivated before 
administration for treatment thus causing harmful effects. 
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 Some soil contains toxic chemicals such as selenium and arsenic which can contaminate 
the plants growing in that particular area (Muhizi, 2002). The contaminated plants can 
cause harmful effects when used as a medicine. 
 The symptoms of the diseases are mostly treated rather than the disease itself because 
majority of the traditional healers are not equipped with the knowledge of the pathology 
of some diseases. They can also diagnose and treat the wrong ailment due to the 
knowledge they have of a different disease which present with same symptoms and was 
treated with the same herb ( Sofowora, 1982; Muhizi, 2002). 
 The growing high demand for medicinal herbs has threatened the existence of some 
plants which can put these plants in the endangered species list thereby leading to 
prohibition of further harvesting by law (Li, 2002). 
 The lack of suitable technology has affected the cultivation of medicinal plants which 
leads to low yield and product of poor quality and can cause possible harm when used as 
medicinal product (Li, 2002). 
 Some of the herbal products on the market are a mixture of two or more herbs and there 
is limited research on the effect of combinations of herbs in humans which can lead to 
possible toxicity when consumed by humans (Li, 2002). 
 Lack of mechanisms to control and regulate TM  advertising and claims (WHO,  2015). 
 Lack of financial support for TM research. 
Some literature has implied that plant medicines can be safer and less damaging to the human 
body than synthetic drugs (Williamson et al., 1996). The market demand for medicinal plants is 
growing at a high and steady rate and is likely to remain high because a lot of the active 
ingredients in the medicinal plant cannot yet be prepared synthetically (Li, 2002).  The increase 
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in medicinal plants research is due to the fact a lot of the commercially important drugs in use 
today were isolated from plants or starting molecules of plant origin such as: digoxin/digitoxin, 
the vinca alkaloids, reserpine and tubocurarine which have all been shown to yield extremely 
valuable molecules that can be used as tools in the characterization of enzymes and classification 
of receptor systems. The efficacy and popularity of medicinal plants have encouraged 
pharmacists and pharmaceutical sciences researchers to carry out thorough analysis on the herbs 
to understand, establish and correlate the relationship between the chemical composition and 
therapeutic activities (Vickery et al., 1979; Bienvenu et al., 2002; Kabatende, 2005). 
 
2.1.3. Basic comparison of Traditional and Modern Medicine. 
Plants were once the only main source of medicine worldwide. New remedies are still been 
obtained from plants on a regular basis. 50% of the drugs in use today are obtained from natural 
products and their derivatives.  Almost 80% of the African population still rely on traditional 
medicines as their primary source of healthcare and in developed countries traditional medicine 
is rapidly gaining recognition. Almost 80% of the population has tried some traditional therapy 
such as homeopathy or acupuncture (Li, 2002; Shetty, 2010). The South African traditional 
medical system has not yet been systematised, and is passed on by word of mouth and learning 
experience from generation to generation. The formal system of medicine, which is well 
documented and systematised, was introduced to South Africa by the Europeans and other 
settlers over three centuries ago which is now practiced and referenced by today’s modern 
western medicine (Van wyk et al., 2000). 
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Each system of medicine is an art of and science of diagnosing the cause of disease, treating the 
disease, and maintain health in the sense of physical, spiritual, social and psychological well-
being. Each system has found solutions to the preventive, promotive and curative aspects of 
healthcare that agrees with the world wide view. For instance, modern medicine may diagnose a 
disease caused by a bacterial infection and treat such disease with an antibiotic while an African 
traditional healer will seek to understand why the patient became ill and presented such 
symptoms in the first place, then treat the cause of the illness, and usually add other therapies to 
alleviate the signs and symptoms of the condition (Van wyk et al., 2000). 
Studies have shown that some modern medicine practitioners believed that it would be beneficial 
to modern medicine if some of traditional medical practices are integrated into their systems. 
Scientists and pharmaceutical companies are urgently searching for new drug sources and 
increasingly turning their eyes to traditional medicines because; it takes years for a new drug to 
be developed and the cost is very high. Furthermore, drug resistance is on the increase which is 
partly due to misuse of medications and has rendered most antibiotics and other drugs used in the 
treatment and management of life threatening disease useless. Foods such as red yeast and oyster 
mushrooms have been used to synthesize compounds such as mevastatin and pravastatin. 
Modern medicine practitioners and pharmaceutical researchers have been able to achieve a few 
successes from the interest in traditional medicine such as the antimalarial drug Artemisinin 
which is derived from the plant, Artemisia annua. In many studies, researchers have pointed out 
the use of traditional medicine as first line of treatment before application of modern drugs 
(Shetty, 2010). 
Modern medicine explains the cause of disease to be due to unwanted pathophysiological agents 
in the body causing the infection, whereas traditional medicines believes that diseases are due to 
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supernatural or spiritual causes or imbalance between forces of nature causing harm to the body. 
New scientific techniques are now being used in the application of traditional medicine during 
the process of new drug discovery from medicinal plants. An example of this new approach is 
reverse pharmacology. The end product is usually the starting point of the research, researchers 
work backwards to find out what a clinically useful compound contains and how it works, since 
most traditional medicine practitioners do not know how most of their remedies work. This new 
approach helps to offer clues about how a particular medicine works and where they exhibit their 
functions in the body (Shetty, 2010). The use of new scientific techniques in plant analysis 
should always take the cultural beliefs and practices into consideration and respect the way 
people use and practice their medicines. 
Some initiatives have been created in Africa such as African network for drug and diagnostics. 
This is an innovation which encourages the mining of Traditional medicines. Global health has a 
lot of benefits to gain from traditional medicine, especially as the need for new drug discovery is 
continuously on the increase. If both modern medicine and traditional medicine can work 
together by collaborating and conributing research capacities equally; there could be a ground 
breaking discovery and revival in health research and development worldwide (Shetty, 2010). 
 
2.1.4. The need for safety and efficacy data 
The use of traditional medicines needs to be properly regulated in order to avoid negative effects 
which could be harmful. The lack of safety and efficacy data on TM has brought several 
challenges to the usage of herbal medicines such as; lack of adequate or accepted research 
methodology for evaluating TM, unpublished data on research in TM, lack of proper training and 
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education about the knowledge of TM practitioners as it relates to its rational use and practice. 
Some scientific evidence which was obtained from randomized clinical trials is only enough for 
the use of few herbal medicines that involve manual therapies and acupuncture (WHO, 2002). 
The world health organization (WHO) has developed strategies to provide support for clinical 
research projects on TM safety and effectiveness including methodologies for research and 
evaluation of TM. The strategies outlined by WHO will help guarantee the safety and efficacy of 
TM and the procedures involved in these therapies. Since the practice of TM relies on a holistic 
approach,  the evaluation of the efficacy of TM has to be done in an integrated manner taking the 
fact that traditional medicine comprises of herbal medicines and traditional procedure-based 
therapies (which can be combined for successful results) into consideration (WHO, 2005; WHO, 
2015).  
Recently, the quality of research has improved and better safety and efficacy data have been 
obtained which have lead to the tremendous increase in the number of patients and medical 
practitioners in developing countries using herbal medicines as an adjunct to or substitute to 
prescription drugs (Li, 2002). WHO provided  statistics which shows the increasing use and 
popularity of traditional medicine in developing countries. The global market for herbal 
medicines currently stands at over 60 billion US dollars annually and is growing steadily (WHO, 
2015). These figures prove that  even with the lack of credible scientific safety and efficacy data,  
the use of herbal medicines will continue to grow so there is a greater need for further research to 
ascertain credible safety and efficacy of traditional medicines and its practice thereof. 
The use of medicinal plants are rapidly regaining their prominent position that they possessed a 
long time ago due to their perceived safety and long history of usage of folk medicines compared 
to drugs manufactured synthetically  Also the fact that plant medicines are natural makes people 
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to trust in their safety. These claims can be detrimental as they are not based on sufficient quality 
clinical data (Amabeoku and Kinyua, 2010). 
A lot of randomized clinical trials are been carried out to authenticate their therapeutic success 
scientifically which will eventually help to speed up the acceptance of medicinal plants into 
modern medicine. Scientific validation increases popularity and approval by practitioners of 
modern medicine in developed and industrialized world such as Europe and the United States of 
America (Amabeoku and Kinyua, 2010). The world health organization has developed strategies 
designed to assists countries develop national policies on the evaluation and regulation of 
traditional medicine practices. These policies help to control and license the use of herbal 
medicines with regards to proper preparation procedure, regulated clinical trials to ensure quality 
and credible safety and efficacy and monitoring of treatment as compared with modern medicine 
(Amabeoku and Kinyua, 2010; WHO, 2015). 
 
2.2 Technologies for herbal medicine discovery and analysis 
2.2.1 Chemical fingerprinting 
Chromatography is a method in drug discovery which is applied to isolate the active ingredients 
from the main plant component and also to shorten the time needed for the isolation. The 
chromatographic methods commonly in use are liquid chromatography, gas chromatography and 
column chromatography. These methods include, combining both natural product chemistry and 
organic synthesis of lead compounds from herbs in drug design and discovery and production of 
samples that are easy to use in screening by purification or fractionation of samples from the 
crude extract. With this done, the final resolution of the active compound is less complex, and 
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additional purification is required. High-performance liquid chromatography (HPLC), nuclear 
magnetic resonance (NMR) and mass spectrometry are used to simplify purification and 
classification of active components from herbal products (Kayprime, 1992; Amabeoku and 
Kinyua, 2010). High-performance liquid chromatography was employed in this study to obtain 
the fingerprint of E. Rhinocerotis for characterization of the plant species.  
 
 2.3 Toxicity and Evaluation of Toxicity 
The scientific study of the harmful effects of chemical compounds on biological components is 
known as toxicology. The harmful effects of the chemicals either occur from the natural part of a 
molecule, or chemical interaction with a particular biological system (Loomis and Hayes, 1996; 
Timbrell, 2001). There is a correlation between the main pharmacological effect of a drug and its 
toxic effects, for example, toxic effects of non steroidal  anti-inflammatory drugs is gastric 
bleeding. Some toxic effects that occur in  therapeutic doses are unpredictable, severe and rare 
while other effects unrelated to the major action of drug are often caused by reactive metabolites 
and/or immunological reactions (Loomis and Hayes, 1996; Rang et al., 2012). 
Before new drugs or food containing chemical components are administered to humans, broad 
toxicological tests are required in order to discover possible toxic substances and the safety limits 
associated with the use of the compounds (Loomis and Hayes, 1996; Amabeoku and Kinyua, 
2010; Rang et al 2012). There are three main methods used to evaluate the toxicity of a 
compound: a) Epidemiology- the process whereby the human, animal or plant populations 
exposed to a chemical compound are been observed. b) in vivo- in vivo administration of test 
compound to the plants or animals under well controlled conditions. c) in vitro- these 
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experiments are carried out by exposing the test compound to cells, sub-cellular fractions or 
single celled organisms and observing them (Timbrell, 2001). Most of the data on the toxicity of 
chemical compounds are obtained from the experimental studies carried out in animals. Hence, 
obtaining the biological information responsible for toxicity that is dose-related, dependable and 
reproducible, and which can be interpreted, extended and/or improved for the assessment of 
health risks to humans should be the main aim of toxicological studies (Ecobichon, 1997; 
Timbrell, 2001). Modern toxicological studies require series of toxicological tests to determine 
the different types of toxicity. The needed tests are reliant on four major principles: species 
selection, group sizes, dose selection and route of administration. There are other points to 
consider apart from the ones previously mentioned, which are, knowledge of the physio-
chemical characteristics of the test compound which is helpful to determine if the compound will 
be toxic or not; the biological considerations, for example, sex of the animals to be used, breed of 
the animals (in or out bred strains), health status of the animal, diet, metabolic similarity to man; 
and finally the duration of the toxicity study (Poole and Leslie, 1989; Timbrell, 2001). 
 
2.4 Species Selection and Group sizes 
Species selection is based on the type of toxicity test carried out. Existing data on the particular 
species, financial and ethical aspects are also considered (Loomis and Hayes, 1996; Rang et al., 
2012). 
When carrying out toxicological studies, there should be enough number of animals to allow 
statistical significance to be calculated. There are three major in vitro safety profiles commonly 
referred to as the 3R’s governing the research involving the use of live laboratory animals. They 
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are, the principle of replacement, reduction and refinement. This entails replacing the live 
animals with other alternatives, reducing the number of test animals and finally, refining the 
existing test methods to decrease unwarrantable suffering to animals. Some literature suggests 
using about six to ten animals per treatment group and a minimal amount of five dosages tested 
in toxicity studies (Poole and Leslie, 1989; Ecobichon, 1997; Timbrell, 2001; Amabeoku and 
Kinyua 2010). 
 
2.5 Route of administration 
The dosing in experimental animals should be performed in the same manner as it would be 
performed in humans according to the guidelines (Rang et al., 2012). The route of administration 
commonly used for most compounds is the oral route. In order to measure the toxicity of 
compounds affected by metabolism or absorption, it is suggested to use the parenteral routes. 
The parenteral route of drug administration involves: injection into the skin (intra-dermal), 
injection beneath the skin (subcutaneous),  injection into the muscle (intramuscular), injection 
into the spine (intra-thecal), injection into the veins (intra-venous) and injection into the arteries 
(intra-arterial). Injection into the abdominal fluid (intra-peritoneal) is the most common route of 
administering test compounds to laboratory animals. The volume of the test compound to be 
administered to test animals requires a stipulated dose and is restricted by the size of the animal, 
hence, there should be maintenance and uniformity of the dose within and between groups of 
animals (Loomis and Hayes, 1996; Timbrell, 2001). The volume of solution administered to test 
animals should always be consistence (expressed as millilitre per kilogram of body weight) and 
must always be maintained as discrepancies in the absorption rates and subsequent biological 
effects could result. Large volumes should be avoided as they are liable to hinder efficient 
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absorption of the toxicant. Volumes ranging between 2.0 to 5.0 ml/kg may be administered 
conveniently to Rodents (Ecobichon, 1992; Amabeoku and Kinyua, 2010). 
It is suggested by literature that the test compound in a toxicological test should be administered 
to the test subjects via a route that the species is prone to get exposed to. In toxicity tests 
involving animals, it is vital to come up with a appropriate means of administering the test 
compound to the animals. The method of intubation or incorporation of the compound in the 
animal feed or drinking water is the simplest way of administering test compound orally to 
animals. However, there is the disadvantages of: the test compound changing the taste of the 
animal feed thereby making it unpleasant  and changing the colour which will result in the 
animal rejecting the feed which will give a false toxicological response. Another disadvantage is 
that mixing the test compound with the animal feed will increase the volume of the feed to be 
ingested by the test animal which will result in imprecise dosing and thus, give false results. 
Practically, the intravenous route is the most convenient way to administer compound to test 
animals as the chemical compounds go directly to the tissue. However, the intravenous route is 
not commonly used in toxicity testing of animals especially rodents because of the rapid 
systemic distribution of the compound in animals resulting in false responses. Therefore, the 
most ideal route of administration is the intraperitoneal route as dose inconsistencies observed 
with oral route, rapid systemic distribution  with the intravenous route and substance 
accumulation at the site of injection observed in other  parenteral routes are all avoided (Poole 
and Leslie, 1989; Ecobichon, 1992; Loomis and Hayes, 1996; Amabeoku and Kinyua, 2010). 
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2.6 Dose selection 
In toxicological studies, there are three doses (high, medium and low) that are the accepted 
dosing schedule designed with a negative control group. This is important in order to 
characterise the toxic response over an experimental dose range, compare the relative toxicity of 
the test compound in different species and also to determine the ‘no-observed-adverse-effect-
level’ (NOAEL). A NOAEL is referred to as the maximum amount of dose administered to an 
experimental animal without producing any toxic effects. It is always associated with the route of 
administration and species of animals used in experiments. It is important to always determine 
the NOAEL so as to ensure that the dose which produces the desired pharmacological effect is 
lower than the dose causing toxic effects (Poole and Leslie, 1989; Loomis and Hayes, 1996;  
Amabeoku and Kinyua, 2010). 
  
2.7 Therapeutic index  
The margin of safety between the dose producing a lethal effect and the dose producing the 
desired effect is referred to as the therapeutic index (TI) (Rang et al., 2012). This is obtained 
experimentally from two dose-response curves obtained on appropriate biological systems of 
animals such as mice or rats. The data represented on one curve is that from the drug’s 
therapeutic effect and the data represented on the second curve is that of the lethal effect of the 
drug. This curve is mainly constructed in order to establish a maximum no-observed-adverse-
effect-level (NOAEL), and also as a proof of potency and safety about the test compound to the 
researcher and regulatory authorities (Loomis and Hayes, 1996; Amabeoku and Kinyua, 2010). 
Comparison of four main statistically obtained values from the dose-response curve which are, 
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LD50, ED50, LD1 and ED99 are used to measure the safety parameters of drugs. The dose which 
will cause mortality in 50% of the animals in a test population is the LD50 and the ED50 is the 
dose which produces the desired response in 50% of test animals. The therapeutic index can be 
obtained in two ways: one is by dividing the LD50 by the ED50 that is representing therapeutic 
index with ratio LD50/ED50. The dose-response relationship is determined by experimental 
administration of the test compound via a particular route of route of administration to groups of 
homogenous species such as mice. It involves dose variation; the initial dose is usually a small 
dose which has no effect on the test animal while subsequent doses are increased in multiples of 
two on a logarithmic basis in preceding group of animals till death of the test animal result from 
the highest dose (Poole and Leslie, 1989; Loomis and Hayes, 1996). There are two major 
limitations to the determination of the therapeutic index of a drug: one is that it does not show 
signs of toxic reactions and secondly, it is based on the data from animal toxicity, which does not 
always reflect forms of toxicity that are clinically important (Rang et al., 2012). 
 
2.8 Toxicity tests 
Toxicity testing entails a firm protocol that vividly outlines the procedures for a specific test. The 
principles of the guidelines require  the type and number of test animals, the particular route of 
compound administration, dose schedules, duration of administration of the test compound and 
thorough pathological and functional procedures should be adhered to (; Loomis and Hayes, 
1996; Amabeoku and Kinyua, 2010). There have been enhancement and modification of toxicity 
testing methods over the years to make them appropriate for different types of toxicity. There are 
three broad categories of toxicity testing: acute toxicity test, sub-chronic toxicity test and the 
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chronic toxicity test (Timbrell, 2001). The acute toxicity test which was carried out in this study 
involves the administration of the test compound on only one occasion. 
 
 2.8.1 Acute toxicity tests 
Acute toxicity test is carried out preceding other toxicity tests on chemical compounds relevant 
to any biological system (Amabeoku and Kinyua, 2010). The aim of this test is to establish the 
symptomatology consequent to administration of the test compound (i.e. the dose response 
relationship) and the order of how lethal the compound is (LD50 value) (Ecobichon, 1992). 
A series of dose-range finding experiments is involved in the establishment of the sequence to 
determine the acute toxicity of a new compound. Subsequent experiments are then performed in 
order to narrow the range of effective doses to measure how lethal the compound is, and finally, 
a perfect experiment for establishing the dose-response curve for lethality is carried out (Loomis 
and Hayes, 1996). In cases where no dose range-finding have been done, four dosages are used 
which may be in logarithmic progression. The data obtained from acute toxicity tests shows a 
dose-response relationship and also reveals toxic effects and time of death (if any) of the test 
animals.  There should be a wide range of doses to allow for manifestation of toxic effects 
associated with the highest dosages used unless the required dose are improbable in relation to 
the expected dose (Ecobichon, 1992; Timbrell, 2001 Amabeoku and Kinyua, 2010). 
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2.8.2 Plant toxicity  
If proper quality control measures are enforced in traditional medicines, a lot of indirect adverse 
effects of herbal medicines could be avoided (Angell and Kassirer, 1998). Some of the toxic 
effects which arise from traditional medicines are due to, misdiagnosis by the traditional 
medicine practitioner or use of wrong herbs, mixing the medicinal plant extract with other toxic 
plant extract or non-organic contaminants such as heavy metals and inclusion of synthetic drugs 
into the natural plant extract; which could have side effects on their own hence aggravating the 
condition (Vickers and Zollman, 1999; Ernst, 2002). Climatic and soil conditions where plants 
are grown, lack of dose-safety studies and variability in chemical components that make up the 
herbs can also cause toxic effects of medicinal plants (Tyagi and Delanty, 2003). Medicinal 
plants should not be viewed as risk-free for they can be linked with toxic effects as a result of the 
plant exposure to the intrinsic ingredients in them. There are various harmful effects of medicinal 
plants. Many plants have the potential to be toxic, carcinogenic, and mutagenic as observed 
through extensive screening program of some South African medicinal plants such as: Tulbaghia 
violacea, Sclerocarya birrea, Prunus africana, Hypoxis colchicifolia and Chaetacme aristata. 
All these plants have the potential to cause long term damage to a patient’s genetic makeup 
(genetoxic) (Fennell et al., 2004). Some other examples of toxic effects of medicinal plants 
include, liver damage resulting from Kava extracts (Ernst, 2002) and brain hemorrhage from 
Ginkgo biloba due to interaction with other platelet inhibitors (Izzo and Ernst, 2001). The same 
thorough and vigorous test applied to synthetic drugs before human consumption should also be 
applied to medicinal plants to ensure optimal safety. 
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2.9 Pathophysiology of epilepsy and antiepileptic drugs 
Epilepsy is a central nervous system disorder characterized by spontaneous, recurring seizures 
associated with loss of consciousness usually but not always with convulsions. The form of the 
seizure depends on the part of the brain affected. Epilepsy is known to affect approximately 0.5-
1% of the worldwide population. The distinguishing sign of epilepsy is the seizure that is mostly 
associated with it. Infants, young children and the elderly are mostly found with epilepsy. 
Females have a higher rate of the disease than males as stated by some literature (Brown et al. 
1993; Cull and Goldstein, 1997; Rang et al., 2015). Causes of seizures include,  brain 
abnormalities, brain infections such as meningitis and encephalitis, neurocysticerosis, stroke, 
head trauma, dementia, and psychotropic drugs known to induce seizures; although the cause in 
adult on-set epilepsy remains unknown (Zeman et al., 2012; Rang et al. 2015). 
The nature of epilepsy is the characteristic seizure mostly associated with epilepsy and high 
episodes of frequently discharged impulses by a group of brain neurons. The abnormal discharge 
can spread to other parts of the brain. The part of the brain where the discharge was first initiated 
and the extent to which the discharge spreads would determines the symptoms produced which 
include the brief lapse of attention to a full convulsing episode alongside other abnormal 
behaviour like the characteristic body movement observed in patients experiencing epileptic 
episodes (Rang et al. 2015). 
Epilepsy is treated mainly with antiepileptic drugs (AEDs). There are a lot of new AEDs 
available today which were developed in the past two decades. They are effective enough in 
controlling about 70% of cases of seizures but their use is limited because of the adverse effects 
they cause. Furthermore, a significant amount of epileptic patients still experience seizures 
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continuously despite being on AEDs.  As a result, research is now focusing more on ways to 
improve their efficacy and adverse effect profiles. The research has been steady but epilepsy still 
remains a very difficult problem to overcome. It has been suggested that the problem might be 
easier to solve if the parts of the brain responsible for emotions, mood and cognitive abilities can 
be controlled (Kabatende 2005; Rang et al., 2015). Low levels of gamma aminobutyric acid 
(GABA), the inhibitory neurotransmitter are often found in the post mortem parts of the brain in 
dead epileptic patients and high levels of glutamate, the excitatory neurotransmitter, is found in 
the post mortem parts of the brain. This can trigger a seizure. Increased intracellular sodium may 
also underlie epilepsy. Therefore, the development of GABA receptor agonist, glutamate 
receptor antagonist and sodium channel inhibitor has been put into consideration as an important 
potential therapeutic strategy when developing drugs for many neurological disorders including 
epilepsy (Barton et al., 2003; Ulbricht and Seamon 2010).  
The spreading of the neuronal excitation occurring during epileptic episodes is prevented by 
anticonvulsants although the mechanisms of how they act are not fully understood. Therefore 
most AEDs are designed to target neuronal mechanisms although a deeper understanding of the 
mechanisms is needed to develop adequate therapies (Devinsky et al., 2013) 
In South Africa, epilepsy is speculated to affect 1 in every 100 person, but more accurate 
statistics is unknown. This is due to the fact that epilepsy statistics are combined with other 
neurological and neurodegenerative illnesses such as schizophrenia, bipolar affective disorder 
and dementia (Keikelame et al., 2012). 
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2.9.1 Neuropathology of epilepsy 
The effects of seizures are intricate and have to be separated from the effects of the major, 
principal neurological disease process that has led to increased susceptibility of seizures. 
Although, there has been proof to support detrimental effects of seizures on brain histology, 
neuropathology is not predictable. Apoptotic (active) or necrotic pathways, gliosis and microglial 
activation may lead to prolonged seizures which may eventually cause neuronal death (Thom et 
al., 2008). 
There are three types of pathology found in the brains of epileptic patients, which are: 
1.) Focal lesions which are the main cause of secondary epilepsy. They include congenital 
malformations, cysts, parasitic infections, abscesses, traumatic lesions and infarcts 
(Webster and Jordan, 1989). There is no distinctive differentiation between focal lesions, 
whether they occur in patients with or without epilepsy. 
2.) Degenerative disease (i.e. diffuse infective): This is not specifically related to epilepsy 
but may be associated with myoclonic and focal seizures. Pathologies such as cerebral 
malaria, leucodystrophies, Huntington’s chorea, Alzheimer’s disease and HIV-associated 
seizures are all included in this group (Webster and Jordan, 1989). 
3.) Epileptic brain damage: a pathological syndrome which occurs differently in idiopathic 
primary epileptic patients or patients whose epilepsy is as a result of generalized or 
partial focal disorder. This type of neuropathology is characterised by extremely selective 
neuronal loss and glial proliferation, which is partially selective and partially diffuse 
(Webster and Jordan, 1989). 
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Some neuropathological alterations may be adaptive and reversible while others are 
permanent (Thom et al., 2008). 
2.9.2 Types of epilepsy 
There are two main categories based on the clinical classification of epilepsy, they include; 
partial and generalized seizures. Although, each has many varieties which are either complex 
(lost of consciousness) or simple (no loss of consciousness) (Rang et al., 2015). 
The particular symptoms produced which determine the type of seizure depend on the part of the 
brain affected, thus convulsions result from involvement of the motor cortex while the peripheral 
autonomic discharge is triggered by the hypothalamus. The loss of consciousness often 
experienced by some epileptics is as a result of the reticular formation in the upper brain stem. 
The type of seizure can be detected by using an electroencephalography (EEG) which involves 
placing electrodes at various points over the scalp to figure out the abnormal electrical activity 
occurring during and after a seizure. Inquiring from a third party about the symptoms displayed 
by the patient during the seizure can also be of help to diagnose epilepsy (Haslett et al., 2002; 
Zeman et al, 2012; Rang et al., 2015). 
 
2.9.2.1 Partial seizures 
In this type of seizure, the discharge starts locally and regularly remains localized. Symptoms 
such as involuntary muscle contractions, autonomic discharge or effects on mood and behaviour 
which are displayed with partial seizures depend on the part of the brain affected. These 
symptoms are referred to as psychomotor epilepsy and patients who experienced them usually 
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have no recollection of the event. The EEG discharge in partial seizures is limited to one brain 
hemisphere. The incidence of partial seizures in epileptic patients increases with age. Partial 
seizures are subdivided into simple partial seizures and complex partial seizures (Rang et al., 
2015). 
 
 
 
 
 
 
 
 
 
 
 
 
Simple partial seizures- Jacksonian epilepsy is a manifestation of partial seizures. This results 
from epileptic focus in the motor cortex which leads to attacks consisting of continuous jerking 
of a specific muscle group. It begins from one side of the body (usually the thumb, big toe or 
 
Fig 2.1: an example of an electroencephalogram (EEG- brain wave recording) showing a focal seizure 
recorded from the scalp. The outstanding ‘spike and wave’ activity observed particularly in ‘C4 P4’ and 
‘P4 O2’ reflects epileptic activity originating over the right side of the brain (Zeman et al., 2012) 
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angle of mouth) and then spreads to the rest of the body within two minutes before ending. 
Patients do not experience loss of consciousness (Rang et al., 2015).  
Complex partial seizures- these are the most common types of epilepsy, patients having this 
type of epilepsy usually experience loss of consciousness mostly at the beginning of epileptic 
attack or later when the discharge has spread from its site of origin (brain) to other parts of the 
brainstem and reticular formation (Rang et al., 2015). 
 
2.9.2.2 Generalized seizures 
The whole brain including the reticular system is involved in this type of seizures. Abnormal 
electrical activity is produced throughout both brain hemispheres. There is immediate loss of 
consciousness experienced in generalized seizures. Generalized seizures are categorized under 
two main types, which are tonic-clonic seizures (grand mal) and absence seizures (petit mal) 
(Rang et al., 2015). 
Tonic-clonic seizures- This seizure usually begins with contraction of the entire body muscles. 
It causes a rigid extensor spasm and the patient cries involuntarily. There is cessation of 
respiration, patient often defecates, micturition and salivation occur. The duration of the tonic 
phase is usually a minute, during which the face turns blue (not syncope), and is followed by a 
series of violent, synchronous jerks that last for about 2-4 minutes. The patient remains 
unconscious for a few minutes after the incidence, followed by a gradual process in recovering 
and also with possible injuries incurred on the patient during the convulsive episode. The 
generalized continuous high-frequency activity which takes place during the tonic phase and the 
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intermittent discharge which occurs in the clonic phase are observed from the EEG readings 
(Rang et al., 2015).  
Absence seizures- This type of seizures mostly occur in children. They are not as dramatic as 
the tonic-clonic seizures but they occur more frequently (lots of seizures in a day) than the tonic-
clonic seizures. During incidence of convulsion, the patient suddenly stops doing anything that 
he/she was doing before, stops speaking in mid-sentence and stares impassively for a few 
seconds with little or no motor disturbance. The patient is not entirely aware of his/her 
environment and recovers at a speedy rate with no attacks afterwards (Rang et al., 2015). A 
characteristic rhythm as seen in the figure below is observed from the EEG during an absence 
seizure attack. 
 
 
 
 
 
 
 
 
 
Some literature has stated that the rhythmic movement is likely caused by oscillatory responses 
which link the cortex and the thalamus to where calcium channels are found expressed by the 
thalamic neurones. This clearly differentiates generalized seizure and partial seizure where the 
.   
Figure 2.2: An example of an EEG showing a brief burst of 3 cycle/seconf ‘spike and wave’ activity 
across the entire scalp from a patient experiencing generalized absence seizure (Zeman et al ., 2012) 
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point of origin and the high-frequency asynchronous discharges spread from a local focus. 
Because of this, modern treatment of epilepsy involves the use of drugs that are able to block the 
calcium channels for treatment of absence seizures,  drugs blocking sodium channels to treat 
generalised and partial tonic-clonic seizures (Ure and Perassolo, 2000; Eadie and Vajda, 2012) 
and drugs which can enhance the inhibition  mediated gamma-aminobutyric acid (GABA) to 
treat generalized and partial tonic-clonic seizures. (Czuczwar and Patsalos, 2001). 
 
2.10 Neurotransmitters in the central nervous system implicated in Epilepsy 
There is synergic relationship between inhibitory and excitatory amino acids which control the 
central nervous system (CNS) (Jansen and Dannhardt, 2003). There are two main categories of 
the amino acids: a) glycine and gamma-aminobutyric acid which are the inhibitory neutral amino 
acids. b) Glutamate which is the excitatory acidic amino acid (Katzung, 2001). Epilepsy is 
thought to arise as a result of imbalance between low levels of gamma-aminobutyric acid 
(GABA) and high levels of glutamic acid activities as shown in the post mortem brains of 
epileptic patients (Rang et al., 2015).  
 
2.10.1 Glutamic acid (glutamate) 
The excitatory amino acid (EAAs) includes glutamate, aspartate and homocysteate. These are the 
major fast excitatory neurotransmitters in the central nervous system (CNS). Glutamate is also 
referred to as L-glutamic acid (Trist, 2000) which mediates the synaptic excitation at major 
synapses in mammalian CNS (Ure et al., 2006). It is common and fairly consistently distributed 
http://etd.uwc.ac.za
 
 
35 
 
in the CNS. Glutamate is more in the CNS than other tissues. The formation of glutamate in the 
CNS is mainly from glucose through the tricarboxylic acid cycle (Krebs cycle) where the glial 
cells synthesis it. It is then taken up by neurons with the aid of some specific transporter proteins 
together with Na+ (sodium ions) and stored in the synaptic vessels which is the main storage site 
for neurotransmitters (Rang et al., 2015). 
Glutamate binds to specific receptors in the CNS; these receptors are widely divided into two 
classes: 1) the ionotropic glutamate receptors (iGluRs) which allow channelling of small 
citations such as Na+ and Ca2+, and 2) the metabotropic glutamate receptors (mGluRs) that 
are responsible for the modulation of second messenger systems (Trist, 2000). The ionotropic 
receptors are subdivided into three main types: N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl Isoxazole-4-proprionic acid (AMPA), and Kainate (Trist, 2000; Ure et al., 
2006;). There is a distinctive difference between the ionotropic receptor and the metabotropic 
receptor in the sense that the ionotropic receptors have a slow rise time, a glycine co-agonist is 
required, the permeability of Ca2+ is high, have voltage-dependent Mg2+ blockade and are 
modulated by Zn2+ and polyamines. While the metabotropic receptors are fast mediators of 
synaptic neurotransmission, permeability of kinetics and Ca2+ are low (Barnard, 1997; Ure et al., 
2006;). The metabotropic receptors are subdivided into eight types (mGlu1-mGlu8), using agonist 
specificity, selective antagonism and structural heterogeneity which are also used to classify 
ionotropic receptors (Rang et al., 2015). Neuronal differentiation, migration of neuron, synapse 
formation and the shaping of axons during early CNS development are all linked to NMDA 
receptors (Sucher, 2006). 
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Over-activation of glutamate receptors may be the cause of many neurodegenerative conditions 
associated with most chronic and acute diseases such as epilepsy, Parkinson’s disease, stroke, 
cerebral ischaemia, Huntington’s disease and AIDs-linked dementia (O’Shea, 2002; Sucher, 
2006).  
Most importantly, glutamate plays a vital role in epileptogenesis and that over stimulation of 
NMDA receptor by glutamate and its glycine co-agonist  causes convulsion. The presence of 
glycine at the NMDA receptor level increases the receptor’s affinity to glutamate (Ure and 
Perassolo, 2000). Hypothetically, the suppression of these seizures would require blockade of the 
action of glutamate on the NMDA receptors. However, studies carried out to determine the 
effectiveness of NMDA antagonist in chemically-induced seizures have been unsuccessful in 
humans, but only successful in animal models. This could be related to the adverse effects 
experienced with classical NMDA antagonists (Dansysz and Parsons, 1998). 
 
2.10.2 Gamma-aminobutyric acid (GABA) 
Amino acids gamma-aminobutyric acid (GABA) and glycine, are the main inhibitory 
neurotransmitters in mammalian central nervous system (CNS). GABA is the major inhibitory 
neurotransmitter in the brain (Rang et al., 2015) with roughly 40% of all cerebral synapses being 
gabaergic (Laube et al., 2002; Amabeoku and Kinyua, 2010). GABA is present in brain tissues 
but not in other mammalian tissues. It is present in lower concentrations but abundant in the 
nigrostriatal system. GABA originates from glutamate by  the glutamic acid decarboxylase 
(GAD) enzyme in GABA-synthesizing neurons present in the brain (Rang et al., 2015). The 
alteration of GABA levels in the brain as well as regulation of GABAergic brain function can 
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occur by physiologically and pharmacologically manipulating the synthesis and catabolism 
(Katzung, 2001; Amabeoku and Kinyua, 2010). 
There are two main types of receptors in GABA mediating activities: the ionotropic (GABAA 
and GABAC) receptors linked to a chloride channel and a G-protein-couple metabotropic 
(GABAB) receptor. GABAA  are found in the post-synaptic part of the brain where there is fast 
mediation of  inhibitory neurotransmission with a high selective permeability for chloride ions  
(Cl–). GABAA receptors are the major targets for some anticonvulsants drugs. The GABAA 
receptor chloride ionophore complex consists of several binding sites for different compounds 
which include gamma aminobutyric acid (GABA) itself, benzodiazepines and barbiturates, some 
convulsant such as picrotoxin (a chloride channel blocker) and bicuculline (a Selective GABAA 
receptor competitive antagonist), neurosteroids which affect inhibitory neurotransmission and 
ethanol (Ure and Perassolo, 2000;  Czuczwar and Patsalos, 2001; Amabeoku and Kinyua, 2010).  
GABAB receptors are located pre-and post-synaptically and directly look like the glutamate 
receptors. They mediate post-and pre-synaptic effects,  inhibiting the postsynaptic excitability 
and also causing decrease in inhibitory and excitatory neurotransmission at both synapses, 
respectively, by enhancing K+ efflux and decreasing Ca2+ efflux (Ure and Perassolo, 2000;  
Czuczwar and Patsalos, 2001; Rang et al., 2015). 
GABAC receptors are found in the retina and they mediate responses through the Cl
– channels 
(Czuczwar and Patsalos, 2001). 
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2.10.3 Glycine  
Just like gamma-aminobutyric acid, glycine increases membrane permeability to Cl– subsequent 
to binding of an agonist to glycine receptors, thus, inhibiting depolarization and firing of neuron 
induced by excitatory neurotransmitters (Barry et al., 1999; Katzung, 2001). 
Glycine’s activity is mediated via the ionotropic glycine receptors (GlyRs) which are, 
strychnine-sensitive glycineA receptor and strychnine-insensitive glycineB receptor (Jansen and 
Dannhardt, 2003; Amabeoku and Kinyua, 2010). The major mediator of fast inhibitory synaptic 
neurotransmission in the mammalian spinal cord and brain stem is the strychnine-sensitive 
gycineA receptor (Breitinger and Becker, 2002). Glycinergic transmission is important in 
controlling motor functions, coordination of reflex responses and processing of sensory signals, 
especially for glycine receptors in the dorsal horn of the spinal cord (Laube et al., 2002; Kirsch, 
2006). 
Compounds such as picrotoxin block the Cl– at the GlyRs, while some anticonvulsants modulate 
GlyRs activity. Furthermore, the GlyR has a high affinity for strychnine, which is a very 
poisonous white odourless alkaloid commonly used as an adulterant for common drugs of abuse 
like cocaine (Katz et al.,1996). Strychnine is a competitive glycine antagonist at the strychnine-
sensitive glycineA receptor. 
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2.11 Epilepsy management 
Administration of antiepileptic drugs (AEDs) is currently the first approach in the clinical 
management of people with epilepsy with the main aim of keeping the patient seizure-free and 
maintaining minimal side effects of the drugs without interference of normal brain function 
(Löscher, 2002a ; Zeman et al., 2012). AED selection is particularly based on its efficacy against 
specific types of seizures, patient’s tolerability and safety. There has been a massive growth in 
AEDs discovery and development in the last two decades, with over twenty various drugs to 
choose from, which includes, lamotrigine, gabapentin, topiramate and tiagabine discovered in the 
20th century, levetiracetam, oxcarbazepine and pregabalin discovered in 21st century. These are 
the newer ‘second generation drugs’. The first generation drugs include the old ones such as: 
phenytoin, carbamazepine, phenobarbital and valproate. AEDs have been known to effectively 
control the seizures in 70-80% of patients. The remaining 20-30% with severe treatment-
refractory epilepsy show no response with conventional AEDs and 5% of these patients are 
eligible for epilepsy neurosurgery (Czuczwar and Patsalos, 2001; Zeman et al., 2012). There has 
been steady progress recently in the pharmacotherapy of epilepsy. In addition to the newly 
discovered drugs, there has been an improvement in the efficacies of the older anticonvulsants 
(McCabe, 2000). 
Despite the advancements in drug discovery, resistance to conventional AEDs has been observed 
in a third of the patients been treated with the drugs.  AEDs do not appear to affect the main 
natural history of epilepsy nor prevent the progression of the disease in  patients who show 
positive response to current pharmacotherapies (Löscher, 2002a) for example after injury to the 
head (Temkin, 2001). Additionally, most of the AEDs are associated with severe adverse effects 
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occurring in approximately 60-70% in epileptic patients on AEDs therapy. Central nervous 
system (CNS) side effects are more common and include symptoms like, fatigue, headache, 
blurred vision, dizziness and some cognitive impairment (Zeman et al., 2012), other adverse 
effects commonly seen in relation to AEDs include, hypersensitivity reactions, teratogenenicity, 
behavioural and mood changes (Rang et al., 2015). Management of epilepsy still lacks complete 
efficiency possibly due to the fact that most AEDs mainly control reverberative neuronal 
discharges whereas, the bigger picture would be to control the areas of the brain functions 
responsible for emotions, mood and cognitive function (Rang et al., 2015). Therefore, another 
area of focus to consider when developing new AEDs would be to develop drugs that prevent 
either the development or progression of epilepsy in addition to developing  drugs used to treat 
patients resistant to the current AEDs (Löscher, 2002a). 
 
2.12 Mechanism of action of antiepileptic drugs 
Antiepileptic drugs act through three main mechanisms: 
 Enhancement of GABA action 
 Inhibition of calcium channel function 
 Inhibition of Sodium channel function 
Other mechanisms include blockade of glutamate receptors to inhibit the effect of glutamic acid 
(Rang et al., 2015). 
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2.12.1 Enhancement of GABA action 
The most commonly used and prescribed AEDs such as: phenobarbital, valproic acid, 
benzodiazepines and some the newer AEDs (vigabatrin and tiagabine) act through this 
mechanism. Most of these AEDs act through GABA-mediated synaptic transmission attained by 
either the enhancement of postsynaptic action of GABA or inhibition of GABA-transaminase 
enzyme (main enzyme responsible for GABA inhibition) (Rang et al., 2015). Some research 
conducted suggested that the enhancement of GABAergic neurotransmission aggravated the 
occurrence of absence seizure using the WAG/Rij rat (a model designed for absence seizure) 
tested with vigabatrin, a GABA transaminase enzyme inhibitor (Marescaux et al., 1992). 
However this research did not help to determine the development of this class of drug, which 
then lead to development of newer AEDs released into the market over the last two decades. 
Although, there is still no improvement in prognosis of refractory epilepsy in epileptic patients 
been treated with these drugs. The lack of sufficient evidence for a rational choice of drug in 
terms of efficacy and/or patient’s tolerability and the many adverse effects associated with these 
AEDs can be the cause of the poor improvement in prognosis of the disease. Other factors beside 
the fact that GABA is a vital factor in epileptogenesis are also considered in the process of AEDs 
research and development (Czuczwar and Patsalos, 2001; Amabeoku and Kinyua, 2010). 
 
2.12.2 Inhibition of calcium channel function 
Many of the AEDs have very little effects on the calcium channels. The main drug that acts 
through this mechanism is ethosuximide. It acts by specific blockage of the T-type calcium 
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channels, consequently controlling the rhythmic discharges associated with generalised absence 
seizures (Rang et al., 2015). 
 
2.12.3 Inhibition of sodium channel function 
A lot of the most important and generally prescribed AEDs such as phenytoin, carbamazepine, 
valproate and lamotrigine acts through this mechanism by affecting the excitability of the 
membrane and acting on the voltage-dependent sodium channels thus blocks the influx of Na+ 
(Rang et al., 2015). This then reduces the number of functional channels capable of generating 
action potentials. There is a high frequency discharge from the neurones during an epileptic 
seizure episode. These AEDs specifically block the channels discriminately to a point whereby 
they are no longer active thus depolarising the neuron (Rang et al., 2015) 
 
2.12.4 Other mechanisms of action of AEDs 
The mechanisms through which many AEDs act are still poorly understood. The barbiturate; 
phenobarbital, for example has more antiepileptic effect and less sedative action compared to 
other barbiturates, but has same GABA-potentiating action. Phenobarbital has same effect on 
convulsions induced electrically and convulsions induced by PTZ in rats or mice, while 
benzodiazepines, whose actions are also on GABA-mediated transmission have no effect on 
convulsions induced electrically. Benzodiazepines such as diazepam prevent the electrical 
activity of neurons within a chemically induced epileptic focus from spreading out of the cortex, 
while phenobarbital decreases the electrical focal activity. Therefore, the action of phenobarbital 
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cannot be only as a result of its interaction with GABA, it is possible that it also acts through 
inhibition of excitatory synaptic responses, but not so much is known about this mechanism of 
action (Rang et al., 2015). 
Many studies have been carried on phenytoin. It has not only been known to cause use-
dependent block of sodium channels but can also affect other areas of membrane function, 
calcium channels included, which could also disturb membrane excitability and synaptic function 
(Rang et al., 2015). 
Levetiracetam and zonisamide, some of the newer AEDs act through poorly understood 
mechanisms but they have been known to have very little or/weak effects on several receptors 
and channels involved in epilepsy (Rang et al., 2015). 
 
2.13 Alternatives to conventional pharmacotherapy of Epilepsy 
Besides the common systemic (oral) administration of AEDs use in treating epilepsy, several 
alternatives or adjunct treatment procedures are being developed for patients experiencing 
resistant and adverse effects from AEDs (Aiken and Brown, 2000). Neurostimulation of the 
vagus nerve by using a neurocybernetic prosthesis implant is one of the most common non-
pharmacological adjunctive therapies for pharmacologically resistant  partial complex epilepsy 
(Morrow et al., 2000). The others include transcranial magnetic stimulation or direct current 
stimulation through the scalp (Ziemann et al., 1998) and electrical stimulation of brain regions 
through depth electrodes (Löscher, 2002a). Placing the epileptic patients on a ketogenic diet is 
another way  to reduce the episodes of neuronal discharge in severe cases of epilepsy in children 
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(Lefevre and Aronso, 2000). Immune therapy (Aarli, 2000), gene therapy (Scheffer and 
Berkovic, 2003), resective surgery for the treatment of drug resistant epilepsy (Beghi and Tonini, 
2006), radio surgery for mesial-temporal and extra-temporal epilepsy management (Romanelli 
and Anschel, 2006), and use of focus-targeted drug treatment, which uses a biosensor device that 
detects the beginning of seizures and then applies treatment to the specific area through a 
minipump to prevent occurrence of seizures (Le Van quyen et al., 2001) have all been used in 
epilepsy. These unconventional methods look promising, therefore, phytomedicines could serve 
as lead compounds in developing the therapeutics that can target GABAA receptors minimal side 
effects and refined therapeutic spectrum (Tsang and Xue, 2004). 
 
2.14 Animal models of Epilepsy  
 The anticonvulsant effect of every first and second generation AEDs was originally determined 
in animal models, therefore the efficacy of AEDs in animal models is still an important factor to 
be considered in new AED research and development (Löscher, 2002b). Since detailed and 
extensive studies are difficult to carry out on epileptic patients, a lot of various animal models of 
epilepsy have been developed (Rang et al., 2015). 
Three main objectives should be of high importance and put into consideration when embarking 
on epilepsy research and new drug development: 1) the Pathophysiology of epilepsy; the basic 
neuronal abnormality in epilepsy should be clearly understood so as to develop  adequate 
therapies intended to avoid epilepsy in patients at risk, 2) the biological mechanisms associated 
with pharmacoresistance and development of drugs capable of reversing or preventing resistance 
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should be clearly understood as well and 3) development of disease-modifying therapies that are 
capable to slow down epilepsy progression (Löscher, 2002b; Rang et al., 2015). 
Two types of animal models are used in epilepsy. A) the acute (reactive or provoked) model: 
this model involves the chemical or electrical induction of seizures in healthy, non-epileptic 
animals (Klitgaard, 2005; Löscher, 2002b) This model uses two major preclinical tools in AEDs 
development, which are the maximal electroshock seizure (MES) and the pentylenetetrazole 
(PTZ)-induced seizure tests. These two acute model tests predict clinical activity and efficacy in 
animal models particularly in mice and rats and are the most important factors to consider in new 
AED research. The MES test is carried out by inducing tonic hind limb seizures electrically in 
animals (Löscher, 2002a; Löscher, 2002b; Klitgaard, 2005) and is used in the early phase of 
AED discovery and it identifies agents with action against generalized tonic-clonic and partial 
seizures. While PTZ-induced seizure test is the most common model. It is mostly used in early 
AED discovery particularly against non-convulsive (generalized) absence or myoclonic seizures. 
PTZ is administered parenterally (Amabeoku and Kinyua, 2010). B) The chronic model 
involves inducing experimental animals electrically or chemically or using animals born with 
epilepsy. The chronic model has helped to improve the testing and development of AEDs. 
Results obtained with the chronic model show that it yields more predictive data and allows for 
more accurate preclinical testing of the efficacy of AEDs (Löscher, 2002a; Lö scher, 2002b; 
Klitgaard, 2005). 
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2.15 Epilepsy management in South Africa: a primary health care concern 
In South Africa, the report of the awareness of the burden of non-communicable disease such as 
epilepsy is growing and yet the burden is unknown, but the incidence is likely to be as huge as 
that typically found in other developing countries around the world (Eastman, 2005). About one 
in every hundred South African suffers from epilepsy, but the figures known are not always 
accurate (Eastman, 2005; Spangenberg and Lalkhen, 2006; Ackerman and Van Toorn, 2011). 
The reason could be that the statistics for epilepsy are combined with those of other neurological 
diseases such as schizophrenia, bipolar disorder and dementia which account for a 6% of the 
total burden of non-communicable diseases (Mayosi et al., 2009). Studies have shown that 
Neurocysticerosis which is one of the causes of epilepsy has a 20% rate of prevalence mainly in 
the rural areas of Eastern Cape Province in South Africa (Mafojane et al., 2003; Foyaca-Sibat et 
al., 2004). The management of epilepsy is regularly accessed through means of clinical 
governance process and in 2011, the Western Cape government, Provincial Department of 
Health reported epilepsy as “a relatively new area for audit” (De Vries, 2011). 
A pilot study carried out by (Keikelame et al., 2012) revealed that the management of epilepsy in 
primary care settings in Cape Town region of South Africa was superficial and poorly taken care 
of.  Factors such as inaccessibility of epilepsy management guidelines and lack of access to 
different range of AEDs, wrong seizure type diagnosis by doctors, poor seizure control (due to 
lack of compliance and drug interactions with alcohol dagga and so on), epileptic patients 
experiencing adverse reactions to AEDs, illiteracy, poverty, lack of continuity of care and poor 
doctor-patient relationship perpetuate the poor management of epilepsy. These reports are 
consistent with reports from other studies regarding the factors related to treatment-gap in sub-
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Saharan Africa (Birbeck, 2010) The fact that there is a wide range of old and new AEDs 
available makes the report about lack of access to different range of AEDs to be of a great 
concern and a disturbing factor. This can lead to patients and health care providers tending to 
accept or ignore side effects due to limited access to various range of AEDs (Belhocine et al., 
2004). Hence, there is an urgent need for integrated and combined approaches to improve the 
management of epilepsy putting the factors responsible for the poor outcomes into consideration 
(Keikelame et al., 2012). 
 
2.16 Description of the plant Elytropappus rhinocerotis 
2.16.1 Introduction 
Elytropappus rhinocerotis belongs to the daisy plant family of Asteracea. E. rhinocerotis is 
common in the Cape region of the Western Cape Province in South Africa. It is among the 
medicinal plants used for the treatment of various ailments by South African traditional medicine 
practitioners (van Wyk et al., 1997). 
This common cape plant is an erect bushy shrub which grows up to 1 to 2 m in height; with tiny, 
greyish-green leaves which are tightly grouped on the thin stems. The flower heads are tiny and 
are not easily seen with a single floret in each (van Wyk et al., 1997). It produces many seeds 
which are borne on each twig. The seeds are tiny and are dispersed by wind by a means of 
feathery pappus. The plants are fast growing and have a long life span. E. rhinocerotis is a 
dominant member of the unique Renosterveld vegetation type in some type of Western and 
Eastern Cape provinces. The species is widely distributed in the Western, Northern and Eastern 
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Cape (van Wyk et al., 1997). It is common and abundant on road verges and can grow in 
disturbed or overgrazed lands.  It is locally known as “renosterbos” in Afrikaans (van Wyk et al., 
1997). 
The tips of the young branches are the parts of the plants used. It is used traditionally to treat 
indigestion, dyspepsia, ulcers and stomach cancer by making infusions of the young branches in 
alcohol. A tonic can also be made from the plant to improve lack of appetite (van Wyk et al., 
1997).  The powdered twigs are used to treat diarrhoea in children. The preparations are said to 
induce sweating and can be used in the treatment of influenza and fevers. It was used as a 
remedy during an influenza epidemic in 1918 and used in the Bredasdorp community in the 
Western Cape to treat epilepsy (Thring and Weitz, 2005). Some of the activity of the medicine is 
due to the chemical Rhinocerotinoic acid which has been isolated from E.rhinocerotis. 
Rhinocerotinoic acid has significant anti-inflammatory activity (van Wyk et al., 1997).  
 Fig 2.3. 
Elytropappus rhinocerotis image sourced from 
https://commons.wikimedia.org/wiki/File:Elytropappus_rhinocerotis_-_Renosterbos_-
_Cape_Town_2.jpg 
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Fig 2.4 structure of Rhinocerotinoic acid sourced from 
http://www.medicinenet.com/seizure/article. 
 
2.16.2 Study Objective 
The use of traditional medicines in particular medicinal plants, in Africa and South Africa 
particularly has long been considered as an important part of the daily lives of individuals and 
their socio-cultural heritage (Van Wyk et al., 2000). Plants were once the only and major source 
of medicine in the world and up till present time, they still continue to provide mankind with new 
remedies. However, the claims made by traditional medicine practitioners regarding the 
therapeutic activity of medicinal plants have not been subjected to enough well and detailed 
scientific evaluation. Therefore, plants with medicinal properties are selected on the basis of their 
perceived ability to treat the particular ailment intended for and frequently used in a manner 
which does not allow pharmacological interpretation of their efficacy (Van Wyk et al., 2000; 
Kabatende, 2005). The validation of the claims made by the traditional healers is required for 
three reasons: firstly, the claims need to be justified so as to ensure the public is exposed to safe 
and efficacious medicines (Chan, 2003; Govender et al., 2006). Secondly, the Medical Research 
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Council of South Africa highly demands proof of efficacy and safety of herbal medicines for the 
purpose of registration and regulation of the products with the main aim of integrating the 
products into the primary health care framework (Govender et al., 2006). Thirdly, despite the 
years of researching epilepsy, neuroscience and pharmacotherapy, positive results in rational 
AED designs was only achieved in the last two decades. Discovery and development of AEDs 
have been especially difficult mainly because of the strict regulatory policies. Clinical trials 
especially, those involving human subjects, have been extremely difficult and challenging due to 
the fact that seizures are erratic in nature due to the complexity of epilepsy (Aiken and Brown, 
2000). Elytropappus rhinocerotis was studied due to the claim of its potential anticonvulsant 
activity by the people in the Bredasdorp community in the Western Cape where it is used for 
convulsions (Thring and Weitz, 2005). This method of practice is not safe because little is known 
about the mechanism of its action and its potential level of toxicity. No scientific data exist about 
E. Rhinocerotis pertaining to its anti-epileptic properties. 
This study, hence, investigated the anticonvulsant activity of E. rhinocerotis by studying the 
effects of the leaf methanol plant extract induced against seizures induced chemically by 
pentylenetetrazole PTZ, picrotoxin, bicuculline, N-methyl-DL-aspartic acid (NMDLA) and 
strychnine in experimental mice. 
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CHAPTER 3   
                              MATERIALS AND METHODS 
 
3.1 plant materials 
3.1.1. Selection, collection and identification of plant material 
Elytropappus rhinocerotis was selected based on documented reported claims by traditional 
healers and a study that was conducted in the Western Cape province of South Africa which 
revealed that the people in the Bredasdorp community use Elytropappus rhinocerotis to treat 
convulsions (Thring and Weitz, 2005). The plant materials, fresh leaves were collected from 
Kirstenbosch National Botanical garden, Cape Town, Republic of South Africa in March 2014. 
A sample of the collected leaves was verified by the curator of the Garden and also authenticated 
by a taxonomist, Mr. Frans Weitz, in the Department of Biodiversity and Conservative Biology 
at the University of the Western Cape and voucher specimen (Amabeoku 008) was deposited in 
the University’s Herbarium. 
 
3.1.2. Preparation of crude methanol extract of E.rhinocerotis 
The freshly collected plant leaves were weighed (3124.3g) and separated from the thin stems. 
The leaves were washed with distilled water, air dried for an hour and dried in a ventilated oven 
at 35oC  for 5 days. The dried leaves (3104.7g) were milled into fine powder using Waring  
(885g) commercial laboratory blender. The fine powder was then stored in amber bottles for 
further use. The dried powder (20g) was extracted in a Soxhlet extractor then in 500ml of 
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methanol for 2 hours. The resultant filtrate was evaporated to a semi-solid extract using a Buchi 
RE11 rotavopour and Buchi 461 water bath. The semi-solid extract was then freeze-dried under 
vacuum at 44oC for 7 days using a freeze-drier to obtain a dried leaf methanol extract (68g) 
which was then stored in an amber bottle in the refrigerator for further use.  
Fresh solutions of E.rhinocerotis were prepared on each day of the experiment by reconstituting  
weighed quantities of the crude leaf methanol extract in a minimum amount of dimethylsulfoxide 
(DMSO) and then made up to appropriate volumes with physiological saline. The plant extract 
was injected intraperitoneally (i.p) into mice in a volume of 1 ml/100g of body weight. 
 
3.2. Experimental animals 
Male albino mice bred in the Animal House of the discipline of Pharmacology, School of 
pharmacy, University of the Western Cape, South Africa, weighing between 18 and 30g were 
used in this study. The mice were housed in groups of eight per cage and had access to food 
(standard mouse pellet diet) and water ad libitum except for the short fasting period prior to the 
commencement of the experiments when they had access only to water. Laboratory conditions of 
temperature (25 ± 1oC), humidity and alternate 12 hour-light and 12 hour-dark cycle were 
maintained at all times during the experiments. Each mouse was used for one experiment only.  
 
3.3 Drugs and chemicals 
Pentylenetetrazole (PTZ, sigma Chemical Co.), picrotoxin (Sigma Chemical Co.), N-methyl-DL-
aspartic acid (NMDLA) (Sigma Chemical Co.), strychnine (Sigma Chemical Co.), muscimol 
(Sigma chemical Co.), LY233053 (Sigma Chemical Co.), phenobarbitone (Gardenyl®, Rhone-
poulene Rorer, South Africa) and 5,5 diphenylhydrantoin sodium salt (Phenytoin, Sigma 
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Chemical Co.) were all dissolved in physiological saline to appropriate volumes. Bicuculline 
(Sigma Chemical Co.) was suspended in 0.5 ml of Tween 80 and adjusted to an appropriate 
volume with physiological saline. Diazepam (Valium®, Roche, South Africa) was suspended in 
a volume of polyethylene glycol 400 (Fluka AG, Buchs) and adjusted to an appropriate volume 
with physiological saline. All drugs were injected intraperitoneally (i.p) in a volume of 1ml/100 
g body weight of animals. Control animals received equal volume injections of the appropriate 
vehicle. Fresh drug solutions were prepared on each day of the experiment. The doses and pre-
treatment times of leaf methanol extract, the standard antiepileptic drugs and DMSO used were 
obtained from previous similar studies (Amabeoku et al., 215). The pre-treatment times 
following the administration of pentylenetetrazole, bicuculline, picrotoxin, strychnine, or 
NMDLA were; plant extract (15 min), phenobarbitone (10 min), diazepam (20 min),  phenytoin 
(20 min), muscimol (1 h), LY233053 (30 min) and DMSO (15 min). 
 
3.4. Phytochemical anaylsis of Elytropappus rhinocerotis 
The methods as described by Harborne (1984) and Ikhiri et al. (1992) were used for the 
phytochemical analysis to detect some of the chemical compounds present in the leaves of 
E.rhinocerotis. 
3.4.1 Alkaloids 
The powdered leaf of E.rhinocerotis (0.5 g)  was boiled with 10 ml of dilute hydrochloric acid 
(alcoholic) in test tube for 5 minutes. The boiled mixture was cooled and the debris was allowed 
to settle. The supernatant liquid was filtered into another test tube and 1ml of the filtrate was 
taken into another test tube to which three drops of dragendorffs’ reagent (potassium bismuth 
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iodide solution) was added. The solution was shaken and observed for the appearance of an 
orange-red spot and the formation of a precipitate which would indicate the presence of 
alkaloids. 
 
3.4.2 Saponins 
 The powdered leaf of E.rhinocerotis  (0.2 g)  was shaken in clean water in a test tube and 
observed for the presence of a persistent froth (foam) which would indicate the presence of 
saponins. 
 
3.4.3 Flavonoids 
The powdered leaf of E.rhinocerotis (10 g)   was boiled for 2 to 3 minutes in 100ml of water in a 
water bath. 3ml of the filtrate was taken into a test tube and 3ml of acid-alcohol (Ethanol: water: 
concentrated hydrochloric acid in a ratio of 1:1:1), solid magnesium (1cm) and 1ml of t-amyl-
alcohol were added. The mixture was then observed for the appearance of a rose-orange or violet 
colour change which would indicate the presence of flavonoids. 
 
3.4.4 Tannins 
The powdered leaf of E.rhinocerotis (0.2g) was boiled in 5ml of water. The mixture was cooled 
and filtered. 2-3 drops of 5% ferric chloride solution were added to the filtrate and observed for 
the formation of a blue-black precipitate which would indicate the presence of tannins. 
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3.4.5 Cardiac glycosides 
The powdered leaf of E.rhinocerotis (0.5g) was boiled in 5ml of 70% ethyl alcohol for 2 
minutes. The mixture was filtered and 10ml of water and 5ml of chloroform were added to the 
filtrate and shaken. The lower chloroform layer was taken off and evaporated to dryness in a 
water bath. The cooled chloroform residue was dissolved in 3ml glacial acetic acid containing 
0.1ml of ferric chloride. The solution was carefully transferred to the surface of 2ml sulphuric 
acid and observed for a reddish-brown layer that was formed at the interface and if the upper 
layer gradually acquired a bluish-green colour that would indicate the presence of cardiac 
glycosides. 
 
3.4.6 Quinones  
The powdered leaf of E.rhinocerotis (10g) was moistened with a 10% hydrochloric acid (HCL) 
solution and allowed to stand in ether: chloroform mixture (3:1, 40ml). The mixture was filtered 
and 1ml of the resultant extract was treated with 1ml of 10% sodium hydroxide (NaOH) solution. 
The solution was observed for the appearance of a red discolouration which would indicate the 
presence of quinones. 
3.4.7 Triterpene steroids 
The powdered leaf of E.rhinocerotis (1g) was extracted for 24 hours in ether. The resultant 
solution was filtered and 1ml of the filtrate evaporated to dryness and the residue was re-
dissolved in several drops of acetic anhydride, several drops of sulphuric acid were then added to 
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the solution which was observed for the appearance of a green colour change which would 
indicate the presence of triterpene steroids. 
  
3.4.8 Reducing sugars 
The powdered leaf of E.rhinocerotis (0.2g) was boiled in 5ml of water; the mixture was cooled 
and filtered. An equal amount of Fehling’s solutions A and B in a ratio 1:1 was added to the 
filtrate and the solution was heated in a water bath. It was then observed for the appearance of a 
red-brown precipitate which would indicate the presence of reducing sugars. 
 
3.5 Acute toxicity testing 
The lethal dose (LD50) of the plant extract was determined using the method of Lorke (1983) as 
modified by Ojewole (2006), and El Hilaly et al. (2004). Mice were fasted for 16 hours. The 
animals were then randomly divided into groups of eight mice per cage. Graded doses of the 
plant extract (100, 200, 400, 800, 1200, 1600, 2000, 2400, 2800, 3200, 3600 and 4000 mg/kg) 
were separately administered orally by means of a bulbed steel needle to the mice in each test 
group. The control group was administered with 0.25ml (p.o) of normal saline by means of a 
bulbed steel needle. The mice in both the control and test groups were then allowed free access 
to food and water, and observed for over 48 hours for signs of acute toxicity such as piloerection, 
salivation, immobility, respiratory distress and death. Log dose-response curves would then be 
constructed for the plant extract from which the lethal dose would be calculated. 
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3.6 PHARMACOLOGICAL SCREENING 
3.6.1 Anticonvulsant activity assessment 
The method described by Vellucci and Webster (1984) and modified by Amabeoku and Chikumi 
(1993), was used to assess the anticonvulsant activity of the leaf methanol extract of E. 
rhinocerotis.  The mice were housed singly in transparent perspex mice cages half an hour prior 
to the commencement of the experiment to adapt to their new environment. Control mice were 
pretreated for 15 min with physiological saline (0.25 ml, i.p.) and then standard convulsant 
agents, such as, PTZ (100 mg/kg, i.p.), bicuculline (30 mg/kg, i.p.), picrotoxin (20 mg/kg, i.p.), 
strychnine (2 mg/kg, i.p.) or  NMDLA (500 mg/kg, i.p.) was administered to induce convulsion 
in the mice. The animals were observed for 30 min for tonic convulsion. Convulsions were 
manifested as tonic hind- limb extensions. The time of the onset of tonic convulsions and the 
number or proportion of animals convulsing or not convulsing were obtained during the 30 min 
observation period. Test animals, eight per group, were pre-treated with either the leaf methanol 
extract of E. rhinocerotis (100-400 mg/kg, i.p.), phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 
mg/kg, i.p.), phenytoin (30 mg/kg, i.p.), muscimol (0.2-2 mg/kg, i.p) or LY233053 (1-5 mg/kg, 
i.p.) prior to the administration of either PTZ, bicuculline, picrotoxin, strychnine or NMDLA.  
The animals were also observed for 30 min for tonic convulsion. The time of the onset of tonic 
convulsions and the number of animals convulsing or not convulsing were obtained during the 
30 min period of observation. The experiment was repeated with another group of eight mice 
pretreated for 15 min with DMSO (0.25 ml, i.p.) prior to the administration of any of the 
convulsant agents. The ability of the plant extract to prevent or delay onset of the tonic hind limb 
extensions was taken as an indication of anticonvulsant activity (Amabeoku et al., 1998, 
Amabeoku and Kinyua, 2010).  
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3.6.2 HPLC analysis 
The HPLC finger print of the plant species  was obtained using standard HPLC chromatographic 
methods Chromatographic system: Agilent 1200 system consisting of degassing system, 
quaternary pump, auto loading sampler, thermostatted column compartment, diode array 
detector, fluorescence detector, analyte fraction collector and Agilent ChemStation software ; 
column: Phenomenex Luna (C18) 5μm and dimensions (250 cm x 4.6 mm). 
 
Chromatographic conditions: Mobile phase degassed with helium, solvent A: water containing 
0.1% formic acid; solvent B: Acetonitrile containing 0.1% formic acid, Mode: flow rate, 0.8 
ml/min; injection volume, 50 μl, detector, UV at 370 nm. The eluent was monitored at several 
wavelengths ranging from 210 to 370nm, the specific wavelength of interest being 350 nm. The 
HPLC operating conditions were programmed to give the following: 0 min, solvent B: 18%; 15 
min, solvent B: 25%; 20 min, solvent B: 35%, 30 min, solvent B: 90%. The run rate was 30 min. 
 
 
3.7 statistical analysis 
The one way of variance (ANOVA) followed by Dunnette’s multiple comparison test (GraphPad 
Prism, version 5.0, GraphPad software, Inc., San Diego Cap 2130, USA), was used to analyze 
the data on the onset of tonic convulsions. The data on the proportion of animals convulsing was 
analyzed using the chi- squared test (Amabeoku and Kinyua, 2010). Data obtained were 
expressed as mean (±SEM). P values of less than 5% (p<0.05) were considered statistically 
significant. 
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3.8 Ethical considerations  
The experimental protocol used in this study was approved (14/7/46) by the University of the 
Western Cape Ethics Committee, Bellville 7535, South Africa and conforms to the University’s 
Regulations Act concerning animal experiments. 
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                                                  CHAPTER 4     
                                                   RESULTS 
 
4.1 Phytochemical Analysis 
The phytochemical tests used to detect the chemical compounds present in the dried powdered 
leaf of E. rhinocerotis leaves indicated the presence of the following chemical compounds; 
alkaloids, saponins, flavonoids, tannins, cardiac glycosides and triterpene steroids (Table 1). 
Table 1. Chemical compounds present in the dried powdered leaf of E. rhinocerotis  
 
Chemical compound 
 
Result  
Alkaloids + 
Saponins + 
Flavonoids + 
Tannins + 
Cardiac glycosides + 
Quinones _ 
Triterpene steroids + 
Reducing sugars _ 
Key 
+ (positive) indicates present 
_ (negative) indicates absent 
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4.2 Acute toxicity test 
Doses of 100-4000 mg/kg of E. rhinocerotis administered orally to mice did not cause any signs 
of acute toxicity or deaths. Therefore, the no-adverse-effect-level (NOAEL) of the plant extract 
was 4000 mg/kg, this being the highest dose tested without any adverse consequence. The LD50 
value obtained for E. rhinocerotis may be greater than 4000 mg/kg (p.o.) (Table 2). 
 
4.3 ANTICONVULSANT ASSESSMENT 
4.3.1 Effect of leaf methanol extract of E. rhinocerotis (ER) on pentylenetetrazole (PTZ) - 
induced seizures  
The dose of 100 mg/kg (i.p.) of pentylenetetrazole (PTZ) manifested tonic convulsions in 100% 
of the experimental animals used. Leaf methanol extract of E. rhinocerotis (100 mg/kg, i.p.) did 
not significantly affect the onset or incidence of the tonic convulsions produced by PTZ 
(100mg/kg, i.p.).  The doses of 200 mg/kg (i.p.) and 400 mg/kg (i.p.) of E. rhinocerotis 
significantly delayed the onset but did not significantly alter the incidence of PTZ (100 mg/kg, 
i.p.)-elicited tonic convulsions.  E. rhinocerotis (400 mg/kg, i.p.) protected only 12.5% of mice 
against the tonic convulsion produced by PTZ (100mg/kg, i.p.). Phenobarbitone (12 mg/kg, i.p.) 
and diazepam (0.5 mg/kg, i.p.) completely protected 100% of the experimental animals used 
against PTZ (100 mg/kg, i.p)-induced tonic convulsion. Muscimol (2 mg/kg, i.p.) significantly 
delayed the onset of tonic convulsion produced by PTZ (100 mg/kg, i.p.) And also significantly 
decrease the proportion of animals convulsing. Muscimol (2 mg/kg, i.p.) protected 62.5% of 
mice against the tonic convulsion. Muscimol (0.2 mg/kg, i.p.) did not significantly affect the 
onset or incidence of the tonic convulsion induced by PTZ (100mg/kg, i.p.).  It protected 25% of 
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mice against the tonic convulsion.  However, combined therapy of the subeffective doses of leaf 
methanol extract of E.rhinocerotis (100 mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p,) significantly 
delayed the onset of tonic convulsion produced by PTZ (100 mg/kg, i.p.) but only protected 25% 
of the number of animals convulsing. The onset or incidence of the tonic convulsion produced by 
PTZ (100mg/kg, i.p) was not significantly affected by either phenytoin (30 mg/kg, i.p) or DMSO 
(0.25 ml, i.p.) (Table 3). 
 
Table 2. Acute toxicity of leaf methanol extract of E. rhinocerotis (ER) in mice  
Dose  
(mg/kg)  
Number of animals 
dead/Number of                     
animals treated 
  Toxic symptoms 
PS (0.25 ml)     0/8  None 
100     0/8  none 
200     0/8  none 
400     0/8  none 
800     0/8  none 
1200     0/8  none 
1600     0/8  none 
2000     0/8  none 
2400     0/8  none 
2800     0/8  none 
3200     0/8  none 
3600                                   0/8                                                                       none                                      
4000                                   0/8                                                                       none 
 
None= no sign of any toxic symptoms observed 
PS: Physiological saline 
4.3.2. Effect of leaf methanol extract of E.rhinocerotis (ER) on bicuculline-induced seizures  
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All the eight experimental animals used experienced tonic convulsions when administered 30 
mg/kg (i.p.) of bicuculline. Leaf methanol extract of E. rhinocerotis (200 and 400 mg/kg, i.p.) 
significantly delayed the onset of bicuculline (30mg/kg, i.p.)-induced tonic convulsion but did 
not significantly affect the proportion of mice convulsing.  E. rhinocerotis (100mg/kg, i.p.) did 
not significantly affect the incidence nor the onset of bicuculline (30 mg/kg, i.p.)-induced tonic 
convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.) and muscimol (2 mg/kg, 
i.p.) significantly delayed the onset of tonic convulsion produced by bicuculline (30 mg/kg, i.p.) 
and also significantly reduced the number of experimental animals convulsing. Phenobarbitone 
(12 mg/kg, i.p.) and muscimol (2 mg/kg, i.p.) protected 75% and 87.5% of the mice against 
bicuculline (30 mg/kg, i.p.)-induced tonic convulsion respectively. Diazepam (0.5 mg/kg, i.p.) 
protected all the mice against the tonic convulsion. The onset or incidence of bicuculline (30 
mg/kg, i.p.)-induced tonic convulsion was not significantly altered by Phenytoin (30 mg/kg, i.p.), 
muscimol (0.2 mg/kg, i.p.) or DMSO (0.25 ml, i.p.). The combined therapy of the subeffective 
doses of leaf methanol extract of E. rhinocerotis (100 mg/kg, i.p.) and muscimol (0.2mg/kg, i.p.) 
did not significantly reduce the number of experimental animals convulsing but significantly 
delayed the onset of bicuculline (30 mg/kg, i.p.)-induced tonic convulsion. The combined 
therapy only protected 50% of the test animals against the tonic convulsion (Table 4).  
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Table 3: Effect of leaf methanol extract of E. rhinocerotis (ER) on pentylenetetrazole (PTZ) 
- induced seizures in mice 
Dose (mg/kg) 
 PTZ      ER      PB    DZ     PHY     MS     DMSO     No. Convulsed/      Percentage                Onset of Tonic 
                                                                     (ml)      No. Used                 protection                 Convulsions(min) 
                                                                                                                     (%)                             Mean ± S.E.M  
100     ─      ─     ─      ─      ─          ─           8/8                     0                        2.13 ± 0.23 
100  100    ─      ─      ─      ─         ─           8/8                      0                        6.38 ± 1.56 
100   200   ─      ─      ─      ─         ─           8/8                      0                       16.1 ±1.20* 
100   400   ─      ─      ─      ─         ─           7/8                    12.5                    16.3 ±2.39* 
100    ─    12      ─     ─       ─         ─           0/8                    100                           0* 
100    ─     ─     0.5    ─       ─         ─           0/8                     100                          0* 
100    ─     ─      ─     30      ─          ─           8/8                      0                        2.09±0.50 
100    ─     ─      ─      ─       2          ─           3/8*                    62                        21.0±4.42* 
100    ─     ─      ─      ─      0.2        ─           8/8                      0                        2.75±0.45 
100   100  ─      ─       ─      0.2        ─           6/8                     25                       17.0±2.94* 
100    ─    ─       ─      ─       ─        0.25         8/8                     0                        2.88±0.48 
*p < 0.001 compared to PTZ (100mg/kg, i.p) control, ANOVA (n=8).  
+p<0.05, ++p<0.001 compared to PTZ (100mg/kg, i.p) control, Chi-squared test (n=8) 
PB: Phenobarbitone 
DZ: Diazepam 
PHY: Phenytoin 
MS: Muscimol 
DMSO: Dimethylsulfoxide 
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Table 4: Effect of leaf methanol extract of E.rhinocerotis (ER) on bicuculline (BIC)-induced 
seizures in mice 
Dose (mg/kg) 
   BIC      ER      PB    DZ     PHY     MS     DMSO    No. Convulsed/    Percentage               Onset of Tonic 
                                                                     (ml)      No. Used                protection                Convulsions(min) 
                                                                                                                     (%)                           Mean ± S.E.M  
30     ─      ─     ─      ─      ─          ─           8/8                     0                         2.38 ± 0.42 
30  100    ─      ─      ─      ─          ─           8/8                     0                         4.76 ± 0.67 
30   200   ─      ─      ─      ─          ─           8/8                     0                         13.38*±1.57 
30   400   ─      ─      ─      ─          ─           8/8                     0                         15.75*±0.49 
30    ─    12      ─     ─       ─          ─            2/8+                   75                        17.93*±1.41    
30    ─     ─     0.5    ─       ─          ─            0/8+++                      100                          0* 
30    ─     ─      ─     30      ─          ─           8/8                      0                         2.44 ± 0.75 
30    ─     ─      ─      ─       2          ─           1/8++                   87.5                    16.98* ±0.87 
30    ─     ─      ─      ─      0.2        ─           8/8                      0                         2.31 ± 0.35 
30   100  ─      ─       ─      0.2       ─           4/8                      50                       15.29*±0.62* 
30    ─    ─       ─      ─       ─        0.25       8/8                      0                          2.41 ± 0.53 
*p < 0.001 compared to bicuculline (30 mg/kg, i.p) control, ANOVA (n=8). 
+p <0.01, ++p<0.005, +++p<0.001 compared to bicuculline (30 mg/kg, i.p) control, Chi-squared 
test (n=8) 
PB: Phenobarbitone 
DZ: Diazepam 
PHY: Phenytoin 
MS: Muscimol 
DMSO: Dimethylsulfoxide 
 
4.3.3 Effect of leaf methanol extract of E.rhinocerotis (ER) on picrotoxin induced seizures  
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All the eight experimental animals used experienced tonic convulsions when administered with 
picrotoxin (20 mg/kg, i.p.). Leaf methanol extract of E.rhinocerotis (200 and 400 mg/kg, i.p.) 
significantly delayed the onset of tonic convulsion produced by picrotoxin (20 mg/kg, i.p.) but 
did not significantly affect the proportion of animals convulsing.  E. rhinocerotis (100 mg/kg, 
i.p.) did not significant affect the onset or incidence of picrotoxin (20 mg/kg, i.p.)-induced tonic 
convulsion. Phenobarbitone (12 mg/kg, i.p.), diazepam (0.5 mg/kg, i.p.) or muscimol (2 mg/kg, 
i.p.) significantly delayed the onset of tonic convulsion induced by picrotoxin (20 mg/kg, i.p.) 
and also significantly reduced the number of experimental animals convulsing. They protected 
87.5% of mice against the tonic convulsions. Muscimol (0.2 mg/kg, i.p.) did not significantly 
affect the onset or the incidence of picrotoxin (20 mg/kg, i.p.)-induced tonic convulsion. 
However, combined therapy of subeffective doses of leaf methanol extract of  E. rhinocerotis 
(100 mg/kg, i.p.) and muscimol (0.2 mg/kg, i.p.) significantly delayed the onset of tonic 
convulsion induced by picrotoxin (20 mg/kg, i.p.) and also significantly reduced the number of 
experimental animals convulsing. The combined therapy protected 62.5% of mice against the 
tonic convulsion. The onset or incidence of picrotoxin (20 mg/kg, i.p.)-induced tonic convulsion 
was not significantly altered by either phenytoin (30 mg/kg, i.p.) or DMSO (0.25 ml, i.p.) (Table 
5).  
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Table 5. Effect of leaf methanol extract of E.rhinocerotis (ER) on picrotoxin (PIC)- induced 
seizures in mice 
Dose (mg/kg) 
   PIC      ER      PB    DZ     PHY     MS     DMSO    No. Convulsed/    Percentage               Onset of Tonic 
                                                                     (ml)      No. Used                protection                Convulsions(min) 
                                                                                                                     (%)                           Mean ± S.E.M  
20     ─      ─     ─      ─      ─          ─           8/8                     0                         8.50 ± 0.42 
20  100    ─      ─      ─      ─         ─           8/8                     0                         9.50 ± 0.57 
20   200   ─      ─      ─      ─         ─           8/8                     0                         16.00* ± 1.22 
20   400   ─      ─      ─      ─         ─           8/8                     0                         19.13* ± 1.18 
20    ─    12      ─     ─       ─       ─            1/8++                 87.5                       20.04**±1.01 
20    ─     ─     0.5    ─       ─         ─           1/8++                87.5                       23.16***±0.84    
20    ─     ─      ─     30      ─          ─           8/8                      0                        9.17±0.33 
20    ─     ─      ─      ─       2          ─           1/8++                 87.5                    28.71***±1.12 
20    ─     ─      ─      ─      0.2        ─           8/8                      0                        10.00±1.08 
20   100  ─      ─       ─      0.2        ─           3/8+                   62.5                    18.29*±1.24 
20    ─    ─       ─      ─       ─        0.25        8/8                      0                        9.17±0.92 
*p < 0.02, **P<0.001 compared to picrotoxin (20 mg/kg, i.p) control, ANOVA (n=8).  
+p<0.05, ++p<0.005 compared to picrotoxin (20 mg/kg, i.p) control, Chi-squared test (n=8). 
PB: Phenobarbitone 
DZ: Diazepam 
PHY: Phenytoin 
MS: Muscimol 
DMSO: Dimethylsulfoxide 
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4.3.4 Effect of leaf methanol extract of E.rhinocerotis (E.R) on Strychnine induced seizures  
Strychnine (2 mg/kg, i.p.) produced tonic convulsions in all the eight animals used. Leaf 
methanol extract of E. rhinocerotis (100 and 200 mg/kg, i.p.) did not significantly affect the 
onset or incidence of strychnine (2 mg/kg, i.p.)-induced tonic convulsion.  Leaf methanol extract 
of E. rhinocerotis (400 mg/kg, i.p.) significantly delayed the onset of tonic convulsion produced 
by strychnine (2 mg/kg, i.p.) but did not affect the number of animals convulsing. 
Phenobarbitone (12 mg/kg, i.p.) significantly delayed the onset of strychnine (2 mg/kg, i.p.)-
induced tonic convulsion and also significantly reduced the number of experimental animals 
convulsing. It protected 62.5% of the animals against strychnine (2 mg/kg, i.p.)-induced tonic 
convulsion. Diazepam (0.5 mg/kg, i.p.), phenytoin (30 mg/kg, i.p.) or DMSO (0.25 ml, i.p.) did 
not significantly alter the onset or incidence of strychnine (2 mg/kg, i.p.)-induced tonic 
convulsion (Table 6).  
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Table 6. Effect of leaf methanol extract of E.rhinocerotis (E.R) on strychnine (STN)-
induced seizures in mice 
Dose (mg/kg) 
   STN      ER      PB    DZ     PHY          DMSO      No.Convulsed/       Percentage               Onset of Tonic 
                                                               (ml)         No.Used                  protection                 Convulsions(min) 
                                                                                                                     (%)                           Mean ± S.E.M  
2      ─       ─     ─      ─               ─           8/8                         0                        2.63±0.26 
2  100      ─      ─      ─              ─           8/8                         0                        3.63±0.18 
2   200     ─      ─      ─              ─           8/8                         0                        3.75±0.16 
2   400     ─      ─      ─             ─           8/8                          0                        11.25*±1.77 
2    ─     12      ─     ─               ─           3/8+                                      62.5                    19.34*±0.65 
2    ─      ─     0.5    ─               ─           8/8                          0                         2.81±0.44 
2    ─      ─      ─     30              ─           8/8                         0                          2.59±0.25 
2    ─      ─      ─      ─              0.25       8/8                         0                          2.76±0.37 
*p < 0.001 compared to strychnine (2 mg/kg, i.p.) control, ANOVA (n=8).   
+p<0.05 compared to strychnine (2 mg/kg, i.p.) control, Chi-squared test (n=8)  
PB: Phenobarbitone 
DZ: Diazepam 
PHY: Phenytoin 
DMSO: Dimethylsulfoxide 
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4.3.5. Effect of leaf methanol extract of E. rhinocerotis (ER) on N-methyl-DL aspartic acid 
(NMDLA)-induced seizures  
NMDLA (500 mg/kg, i.p.) produced tonic convulsions in the eight experimental animals used. 
Leaf methanol extract of E. rhinocerotis (400 mg/kg, i.p.) significantly delayed the onset but did 
not significantly affect the incidence of NMDLA (500 mg/kg, i.p.)-induced tonic convulsion.  E. 
rhinocerotis (400 mg/kg, i.p.) protected only 12.5% of the test animals from convulsing. The 
doses of leaf methanol extract of E. rhinocerotis (100 and 200 mg/kg, i.p.) had no significant 
effect on the onset and incidence of NMDLA (500 mg/kg, i.p.)-induced tonic convulsion. The 
onset or incidence of NMDLA (500mg/kg, i.p) induced tonic convulsion was not significantly 
altered by phenobarbitone (12 mg/kg, i.p.), diazepam (0.5mg/kg, i.p.), phenytoin (30 mg/kg, i.p.) 
or DMSO (0.25 ml, i.p.). LY233053 (5 mg/kg, i.p.) significantly delayed the onset of tonic 
convulsion induced by NMDLA (500 mg/kg, i.p.) and also significantly reduced the number of 
experimental animals convulsing. This dose protected 87.5% of mice against the tonic 
convulsion. LY233053 (1mg/kg, i.p) had no significant effect on the onset and incidence of the 
tonic convulsion produced by NMDLA (500 mg/kg, i.p.). However, the combined therapy of the 
subeffective doses of LY233053 (1 mg/kg, i.p.) and leaf methanol extract of E. rhinocerotis (100 
mg/kg, i.p.) significantly delayed the onset of NMDLA (500mg/kg, i.p.)-induced tonic 
convulsion but did not significantly affect the number of the experimental animals convulsing 
(Table 7).  
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Table 7: Effect of leaf methanol extract of E. rhinocerotis (ER) on N-methyl-DL aspartic 
acid (NMDLA) induced seizures in mice 
Dose (mg/kg) 
 NMDLA  ER      PB    DZ     PHY     LY     DMSO    No. Convulsed/    Percentage              Onset of Tonic 
                                                                       (ml)      No. Used                 protection             Convulsions(min) 
                                                                                                                     (%)                           Mean ± S.E.M  
 
*P < 0.01, **P <0.005, ***P<0.001 compared to NMDLA (500mg/kg, i.p) control, ANOVA 
(n=8). +P<0.005 compared to NMDLA (500mg/kg, i.p) control, Chi-squared test (n=8). 
PB: phenobarbitone 
DZ: Diazepam 
PHY: phenytoin 
LY: LY233053 
DMSO: Dimethylsulfoxide. 
500      ─       ─     ─      ─      ─          ─           8/8                     0                        4.38±0.32 
500  100      ─      ─      ─      ─         ─           8/8                     0                        6.38±0.53 
500   200     ─      ─      ─      ─         ─           8/8                     0                        7.25±0.25 
500   400     ─      ─      ─      ─         ─           7/8                     12.5                   12.38**±2.54 
500    ─     12      ─     ─       ─       ─              8/8                     0                       4.19±0.12 
500    ─      ─     0.5    ─       ─         ─           8/8                      0                       5.03±0.84 
500    ─      ─      ─     30      ─          ─          8/8                      0                       4.46±0.38 
500    ─      ─      ─      ─       5          ─          1/8+                  87.5                    22.13***±0.98 
500    ─      ─      ─      ─       1        ─           8/8                      0                        7.20±0.65 
500   100   ─      ─       ─       1        ─           8/8                       0                       10.88*±0.71 
500    ─     ─       ─      ─       ─        0.25       8/8                      0                       4.29±0.55 
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4.4 HPLC ANALYSIS 
The HPLC fingerprint of the leaf methanol extract of Elytropappus rhinocerotis showed distinct 
peaks at the following retention times, 4.227, 5.030, 7.698, 12.810, 13.306, 15.333 and 18.563 
min 
 
 
Fig.4.1. HPLC fingerprint of leaf methanol extract of Elytropappus rhinocerotis 
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                                                              CHAPTER 5  
                                 DISCUSSION AND CONCLUSION 
5.1 DISCUSSION 
The study investigated the anticonvulsant activity of the leaf methanol extract of Elytropappus 
rhinocerotis by studying the effect against tonic convulsions produced by pentylenetetrazole 
(PTZ), bicuculline, picrotoxin, strychnine or N-methyl-DL-aspartic acid (NMDLA). The leaf 
methanol extract of E. rhinocerotis (200-400 mg/kg, i.p.) was shown in this study to antagonize 
tonic convulsions produced by PTZ (100 mg/kg, i.p.), bicuculline (30 mg/kg, i.p.), picrotoxin (20 
mg/kg, i.p.), strychnine (2 mg/kg, i.p.) or NMDLA (500 mg/kg, i.p.). Phenobarbital (12 mg/kg, 
i.p.), diazepam (0.5 mg/kg, i.p.), muscimol (2 mg/kg, i.p.) or muscimol (0.2 mg/kg, i.p.) + leaf 
methanol extract of E. rhinocerotis (100 mg/kg, i.p.) antagonized PTZ (100 mg/kg, i.p.), 
bicuculline (30 mg/kg, i.p.) or picrotoxin (20mg/kg, i.p.)-elicited tonic convulsions. 
Phenobarbital (12 mg/kg, i.p.) or leaf methanol extract of E. rhinocerotis (400 mg/kg, i.p.) and 
not diazepam (0.5 mg/kg,i.p.) antagonised strychnine (2 mg/kg, i.p.)-elicited tonic convulsion. 
LY233053 (5 mg/kg, i.p.), leaf methanol extract of E. rhinocerotis (400 mg/kg, i.p.) or 
LY233053 (1 mg/kg, i.p.) + leaf methanol extract of E. rhinocerotis (100 mg/kg, i.p.)  But not 
phenobarbital (12 mg/kg, i.p.) or diazepam (0.5 mg/kg, i.p.) antagonized the tonic convulsion 
produced by NMDLA (500 mg/kg, i.p.). Phenytoin (30 mg/kg, i.p.) or DMSO (0.25 ml, i.p.) did 
not affect tonic convulsions produced by PTZ (100 mg/kg, i.p.), bicuculline (30 mg/kg, i.p.), 
picrotoxin (20mg/kg, i.p.), strychnine (2 mg/kg, i.p.) or NMDLA (500 mg/kg, i.p.). 
According to Meldrum (1975), Olsen (1981), Czuczwar and Patsalos (2001) and Rang et al. 
(2015), gamma aminobutyric acid, a major inhibitory neurotransmitter in the CNS, facilitates 
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increased chloride ion conductance into the brain cells by stimulating GABAA receptors to open 
the GABAA-linked chloride channels. This enhances GABA neurotransmission and antagonises 
convulsions while inhibition of GABA mediated neurotransmission at GABAA receptors causes 
convulsion. On the other hand, stimulation of NMDA receptors by glutamic acid in the CNS 
enhances glutamic acid neurotransmission and causes convulsions while inhibition of the 
neurotransmission antagonises the convulsions. Pentylenetetrazole (PTZ) was shown in the study 
to induce tonic convulsion in the experimental animals. According to Kalant and Roschlau 
(1998), De Sarro et al.(1999) and Rang et al. (2015), PTZ produces convulsion by inhibiting 
GABA Neurotransmission at the GABAA receptors in the brain.  Phenobarbitone and diazepam, 
standard antiepileptic drugs, exhibit their anticonvulsant effects by increasing GABA mediated 
inhibition in the brain through the GABAA receptor ionophore complex (Kalant and Roschlau 
1998; Rang et al. 2015). The data obtained in this study show that phenobarbitone and diazepam 
significantly antagonized PTZ- induced seizures which may probably be due to their activating 
GABA mechanism. On the other hand, phenytoin, a standard antiepileptic drug, did not affect 
PTZ-induced tonic convulsion because it exerts its anticonvulsant effect by inhibiting sodium ion 
entry into the brain cells resulting in the inhibition of the generation of repetitive action potential 
(Kalant and Roschlau 1998; Rang et al. 2015). Muscimol was shown in the study to significantly 
antagonise PTZ- induced tonic convulsions. This may be due to muscimol being a specific 
GABAA receptor agonist and produces similar effect to that of GABA by stimulating GABAA 
receptor in the brain (Lanca, 1998; Rang et al., 2015). Leaf methanol extract of E. rhinocerotis 
(200 and 400 mg/kg, i.p.) and a combined therapy of the subeffective doses of muscimol (0.2 
mg/kg, i.p.) and leaf methanol extract of E. rhinocerotis (100 mg/kg, i.p.) significantly 
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antagonised PTZ- induced tonic convulsions which may probably be due to enhancement of 
GABA neurotransmission. 
Bicuculline, a known potent and specific GABAA receptor antagonist in the brain (Lanca, 1998; 
Rang et al., 2015), was shown to produce tonic convulsions in the present study. Phenobarbitone 
and diazepam known to antagonize convulsions by  
Increasing GABA neurotransmission through GABAA receptor ionophore complex  
(Kalant and Roschlau 1998; Rang et al. 2015), were shown to antagonize bicuculline-induced 
tonic convulsion. In addition, muscimol, a specific GABAA  
Receptor agonist, known to have anticonvulsant property (Lanca, 1998; Rang et al.,2015), 
significantly antagonized bicuculline-induced tonic convulsion. However, phenytoin known to 
have anticonvulsant effect by blocking sodium channel and hence blocking sodium ion entry into 
brain cells (Rang et al., 2016) did not affect bicuculline-induced tonic convulsion.  Leaf 
methanol extract of E. rhinocerotis (200 and 400 mg/kg, i.p.) and a combined therapy of the 
subeffective doses of muscimol (0.2 mg/kg, i.p.) and leaf methanol extract of E. rhinocerotis 
(100 mg/kg, i.p.) significantly antagonised bicuculline- induced tonic convulsions. This 
therefore, supports the assertion that GABA mechanism may be involved in the anticonvulsant 
activity of the leaf methanol extract of E. rhinocerotis.  
According to Kalant and Roschlau (1998) and Rang et al. (2015), picrotoxin, a GABAA receptor 
antagonist, blocks GABA neurotransmission and causes convulsion by binding to its binding site 
inside the GABAA receptor-linked chloride channel. This blocks the chloride channel and 
inhibits the entry of chloride ions into the brain. Picrotoxin produced tonic convulsion in 
experimental mice in the present study. It is not surprising therefore, that, in this study, 
phenobarbitone and diazepam, or muscimol known to enhance GABA neurotransmission or 
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mimic the effect GABA at GABAA receptor respectively (Lanca 1989, Rang et al., 2016), 
antagonised the tonic convulsion produced by picrotoxin. Phenytoin known to prevent 
convulsion by blocking sodium channel and hence blocking sodium ion entry into brain cells 
(Rang et al., 2016), did not affect picrotoxin-induced tonic convulsion.  Similar to 
phenobarbitone and diazepam, leaf methanol extract of E. rhinocerotis (200 and 400 mg/kg, i.p.) 
and a combined therapy of the subeffective doses of muscimol (0.2 mg/kg, i.p.) and leaf 
methanol extract of E. rhinocerotis (100 mg/kg, i.p.) significantly antagonised picrotoxin-
induced tonic convulsions. This therefore, further supports the assertion that GABA mechanism 
may be involved in the anticonvulsant activity of the leaf methanol extract of E. rhinocerotis. 
In the present study, strychnine produced tonic convulsion in experimental animals. Strychnine, 
a selective glycine receptor antagonist, exerts its convulsant effect by blocking glycine receptor 
which is also linked to chloride channel in the brain (Lanca, 1998,; Rang et al., 2016). 
Phenobarbitone and leaf methanol extract of E. rhinocerotis (400 mg/kg, i.p.) were shown in the 
study, to significantly antagonised strychnine-induced tonic convulsions. However, diazepam 
and phenytoin did not affect the tonic convulsion produced by strychnine. The above data 
indicate that the anticonvulsant activity of leaf methanol extract of E.rhinocerotis may be 
underpinned by the enhancement of glycine neurotransmission. Report by Rang et al. (2015) 
showed that besides enhancing 
GABA neurotransmission to prevent convulsion, phenobarbitone may also have other 
mechanisms involved in its anticonvulsant activity.  Since it was shown in  
the study to antagonize strychnine-induced tonic convulsion, it is probable that glycine 
mechanism may be involved in the anticonvulsant activity of phenobarbitone in the brain. Rang 
et al. (2015) have also reported that benzodiazepines do not to affect convulsion produced by 
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strychnine in experimental animals. It is not surprising therefore, that diazepam, a 
benzodiazepine, did not alter strychnine-induced tonic convulsion in the study.   
 
However, it is important to mention that according to Lambert et al. (1981) and Boyd et al. 
(1983) , moderate to high doses of IV phenobarbitone, IV diazepam and IV phenytoin have been 
effective in the prevention of strychnine convulsion in people suffering from strychnine 
poisoning. 
 
The present study shows that N-methyl-DL-aspartic acid (NMDLA) produced tonic convulsion 
in experimental animals. The reports by Chapman and Meldrum (1991), Besancon et al. (2008) 
and Rang et al. (2015) show that NMDLA produces convulsion by stimulating NMDA receptors 
in the brain to produce effects similar to that of glutamate, the excitatory amino acid implicated 
in epilepsy.  
The data obtained in the study show that, phenobarbitone, and diazepam, known enhancers of 
GABA neurotransmission, and phenytoin, known blocker of sodium ion entry into the brain, did 
not affect NMDLA-induced tonic convulsion. LY233053, a competitive NMDA receptor 
antagonist, known to prevent glutamic acid-induced convulsion by blocking glutamic acid effect 
at NMDA receptors  
(Madden et al., 1992; Borowicz et al., 1996), was shown to block NMDLA-induced tonic 
convulsion in the study. Similar to LY233053 (5 mg/kg, i.p.), leaf methanol extract of E. 
rhinocerotis (400 mg/kg, i.p.) and a combined therapy of the subeffective doses of LY233053 (1 
mg/kg, i.p.) and leaf methanol extract of E.rhinocerotis (100 mg/kg, i.p.) significantly 
antagonised NMDLA-induced tonic convulsions indicating the possibility of the involvement of 
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glutaminergic mechanism in the anticonvulsant activity of leaf methanol extract of E. 
rhinocerotis.    
The phytochemical analysis, in this study, reveals the presence of alkaloids, saponins, 
flavonoids, tannins, cardiac glycosides and triterpene steroids in the leaves of Elytropappus 
rhinocerotis. This is in addition to the labdane diterpene, rhinocerotinoic acid, which is 
responsible for the anti-inflammatory activity (Dwarka, 2012). Triterpene steroids have been 
shown to possess strong anticonvulsant activity in various medicinal plants (ihumans, 2001; 
Chauhan et al.,1998; Amabeoku and Kinyua, 2010). Terpenoids includes saponins and triterpene 
steroids. It is therefore, possible that the saponins and triterpene steroids present in the plant 
species may be contributing to its anticonvulsant activity. The LD50 value proposed for the leaf 
methanol extract of E. rhinocerotis administered orally should be over 4000 mg/kg since no 
death of the animals was observed at this dose in the study. It is pertinent to mention that the 
leaves of E. rhinocerotis are given orally as an infusion by traditional medicine practitioner. 
Therefore, the LD50 value obtained shows that the plant material is non toxic to the mice used. 
The HPLC fingerprint obtained becomes very important because of the characteristic peaks 
shown by the fingerprint which could be useful in the verification of this species of plant. 
 
5.2 CONCLUSION 
The results of this study confirm that Elytropappus rhinocerotis possesses strong anticonvulsant 
activity; thus affirming its use by the traditional medicine practitioners in Western Cape region 
of South Africa in treating convulsions. Other findings from this study suggest the involvement 
of gabaergic, glutaminergic and  
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Glycinergic systems to control chemically-induced seizures by the leaf methanol extract of 
Elytropappus rhinocerotis. It is therefore possible to suggest that more than one mechanism may 
be involved in the plant’s anticonvulsant activity. The oral acute toxicity study shows that 
Elytropappus rhinocerotis is conveniently safe at all oral doses tested as neither lethality nor 
unpleasant behaviour of animals were observed.  
 
5.3 FURTHER WORK 
Further work should include an elaborate toxicological studies and clarification of the 
mechanism (s) by which the plant species produces its anticonvulsant activity. 
 
 
 
 
 
 
 
                                               
 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za
 
 
80 
 
REFERENCES 
Aarli, J.A., 2000. Epilepsy and the immune system. Archives of neurology,57(12), pp.1689-1692. 
 
Ackermann, S.A.L.L.Y. and Van Toorn, R.O.N.A.L.D., 2011. Managing first-time seizures and 
epilepsy in children: A first seizure is a relatively common problem in paediatric general 
practice. Continuing Medical Education, 29(4). 
 
Aiken, S.P. and Brown, W.M., 2000. Treatment of epilepsy: existing therapies and future 
developments. Front Biosci, 5, pp.E124-52. 
 
Amabeoku GJ, central nervous system pharmacology, PHA 323 course reader. 
 
Amabeoku GJ,  Ahmad AH, 2013. Involvement of Gamma Aminobutyric Acid in the 
anticonvulsant effect of the leaf methanol extract of Ruta graveolens L. (Rutaceae) in mice. 
Int.J.Pharmacol. 9(2):134-142. 
 
Amabeoku G.J and Chikuni, O, 1994. Gabaergic and dopaminergic systems may be involved in 
seizures induced by pyrimethamine in mice. Gen. Pharmacol. 25 (6): 1269-1277. 
Amabeoku, G.J. and Kinyua, C.G., 2010. Evaluation of the anticonvulsant activity of 
Zanthoxylum capense (Thunb.) Harv.(Rutaceae) in mice. Int J Pharmacol, 6(6), pp.844-53. 
 
Amabeoku, G.J., Mbamalu, O.N., Davids, T., Fakude, S., Gqwaka, A., Mbai, F., Pieterse, R. and 
Shaik, A., 2014. Evaluation of the Anticonvulsant Activity of the Leaf Methanol Extract of 
Crassula arborescens (Mill.) Willd.(Crassulaceae) in Mice. Journal of Pharmacy and 
Pharmacology, 2, pp.393-403. 
http://etd.uwc.ac.za
 
 
81 
 
 
Angell, M. and Kassirer, J.P., 1998. Alternative medicine-the risks of untested and unregulated 
remedies. New England Journal of Medicine, 339, pp.839-840. 
 
Atta, A.H. and Alkofahi, A., 1998. Anti-nociceptive and anti-inflammatory effects of some 
Jordanian medicinal plant extracts. Journal of ethnopharmacology, 60(2), pp.117-124. 
 
Barnard, E.A., 1997. Ionotropic glutamate receptors: new types and new concepts. Trends in 
pharmacological sciences, 18(4), pp.141-148. 
 
Barry, P.H., Schofield, P.R. and Moorhouse, A.J., 1999. Glycine receptors: what gets in and 
why?. Clinical and experimental pharmacology and physiology, 26(11), pp.935-936. 
Barton, M.E., Steven, C.P. and Harlan, E.S. (2003). Comparison of the effect of glutamate 
receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy research, 
56: 17-26. 
 
Beghi, E. and Tonini, C., 2006. Surgery for epilepsy: assessing evidence from observational 
studies. Epilepsy research, 70(2), pp.97-102. 
 
Belhocine M, De Boer HM, Mandlhate C. Epilepsy in the WHO African Region: bridging the 
gap. WHO; 2004. P.1-48. 
 
http://etd.uwc.ac.za
 
 
82 
 
Besancon, E., Guo, S., Lok, J., Tymianski, M. and Lo, E.H., 2008. Beyond NMDA and AMPA 
glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends 
in pharmacological sciences,29(5), pp.268-275. 
 
Bienvenu, E., Amabeoku, G.J., Eagles, P.K., Scott, G. and Springfield, E.P., 2002. 
Anticonvulsant activity of aqueous extract of Leonotis leonurus.Phytomedicine, 9(3), pp.217-
223. 
 
Birbeck, G.L., 2010. Epilepsy care in developing countries: part I of II.Epilepsy Currents, 10(4), 
pp.75-79. 
 
Borowicz, K.K., Gasior, M., Kleinrok, Z. and Czuczwar, S.J., 1996. Competitive 
NMDA‐ Receptor Antagonists, LY 235959 and LY 233053, Enhance the Protective Efficacy of 
Various Antiepileptic Drugs Against Maximal Electroshock‐ Induced Seizures in 
Mice. Epilepsia, 37(7), pp.618-624. 
 
Boyd, R.E., Brennan, P.T., Deng, J.F., Rochester, D.F. and Spyker, D.A., 1983. Strychnine 
poisoning: recovery from profound lactic acidosis, hyperthermia, and rhabdomyolysis. The 
American journal of medicine, 74(3), pp.507-512. 
Brams, M., Pandya, A., Kuzmin, D., van Elk, R., Krijnen, L., Yakel, J.L., Tsetlin, V., Smit, A.B. 
and Ulens, C., 2011. A structural and mutagenic blueprint for molecular recognition of 
strychnine and d-tubocurarine by different cys-loop receptors. PLoS Biol, 9(3), p.e1001034. 
Breitinger, H.G. and Becker, C.M., 2002. The inhibitory glycine receptor—simple views of a 
complicated channel. Chembiochem, 3(11), pp.1042-1052. 
 
http://etd.uwc.ac.za
 
 
83 
 
Brown, S., Betts, T., Chadwick, D., Hall, B., Shorvon, S and Wallace, S.(1993). An epilepsy 
needs document. 
 
Campaign, T.A. & Richter, M., 2003. Traditional Medicines and Traditional Healers in South 
Africa.  
 
Chan, K., 2003. Some aspects of toxic contaminants in herbal medicines.Chemosphere, 52(9), 
pp.1361-1371. 
 
Chapman, A.G., Smith, S.E. and Meldrum, B.S., 1991. The anticonvulsant effect of the non-
NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy research, 9(2), pp.92-96. 
 
Chauhan, A.K., Dobhal, M.P. and Joshi, B.C., 1988. A review of medicinal plants showing 
anticonvulsant activity. Journal of ethnopharmacology, 22(1), pp.11-23. 
 
Cull, C. and Goldstein, L.H., 1997. The clinical psychologist's handbook of epilepsy: assessment 
and management. Psychology Press. 
 
Cunningham, A.B., 1997. An Africa-wide overview of medicinal plant harvesting, conservation 
and health care. Medicinal plants for forest conservation and health care, 11, pp.116-129. 
Czuczwar, S.J. and Patsalos, P.N., 2001. The new generation of GABA enhancers. CNS 
drugs, 15(5), pp.339-350. 
http://etd.uwc.ac.za
 
 
84 
 
 
Dansynz, W. and Parsons, C.G. (1998). Glycine, NMDA receptors –physiological significance 
and possible therapeutic applications. Pharmacological Reviews. 50: 597-664. 
 
De Sarro, G., Palma, E., Costa, N., Marra, R., Gratteri, S., De Sarro, A. and Rotiroti, D., 2000. 
Effects of compounds acting on GABA B receptors in the pentylenetetrazole kindling model of 
epilepsy in mice. Neuropharmacology,39(11), pp.2147-2161. 
 
De Vries, E. integrated chronic disease audit report. Department of health, provincial 
Government of the Western Cape; 2011. P. 1-11. 
 
Dwarka, D., 2012. Anti-carcinogenic activity of Centella asiatica and Elytropappus rhinocerotis 
on a human colon cancer cell line (Doctoral dissertation). 
 
Eadie, M.J. and Vajda, F. eds., 2012. Antiepileptic drugs: pharmacology and therapeutics (Vol. 
138). Springer Science & Business Media. 
Eastman, R., 2005. Epilepsy in South Africa. Acta Neurologica Scandinavica,112(s181), pp.8-
11. 
 
Ecobichon, D.J., 1997. The basis of toxicity testing. CRC press.pp.7-58 
 
 
Ernst, E., 2002. Complementary and alternative medicine in neurology: hype, hope and 
hazards. Trends in neurosciences, 25(12), pp.644-645. 
http://etd.uwc.ac.za
 
 
85 
 
 
Fennell, C.W., Lindsey, K.L., McGaw, L.J., Sparg, S.G., Stafford, G.I., Elgorashi, E.E., Grace, 
O.M. and Van Staden, J., 2004. Assessing African medicinal plants for efficacy and safety: 
pharmacological screening and toxicology. Journal of Ethnopharmacology, 94(2), pp.205-217. 
 
Foyaca-Sibat, H., Del Rio, A.I. and Ibanez-Valdes LdeF, V.N.E., 2004. del C, Awotedu AA. 
Neuroepidemiological survey for epilepsy and knowledge about neurocysticercosis at 
Sidwadweni location, South Africa. Electronic Journal of Biomedicine, 2(1), pp.40-48. 
 
Frolund, B., Ebert, B., Kristiansen, U., Liljefors, T. and Krogsgaard-Larsen, P., 2002. GABA-A 
receptor ligands and their therapeutic potentials. Current topics in medicinal chemistry, 2(8), 
pp.817-832. 
Govender, S., Du Plessis-Stoman, D., Downing, T.G. and Van de Venter, M., 2006. Traditional 
herbal medicines: microbial contamination, consumer safety and the need for standards. South 
African Journal of Science, 102. 
 
Grammes-Smith, D.G and Aronson, J.K. (1984). Oxford Textbook of Clinical Pharmacology and 
Drug therap. Oxford University Press, London, pp, 501-553. 
Harbone J.B. (1984). Phytochemical Methods: A guide to Modern Techniques of Plant Analysis. 
2nd Edn., London: Chapman and Hall.  
 
Haslett, C., Chilvers, E.R., Boon, N.A., Colledge, N.R. and Hunter, J.A.A., 2002. Davidson’s 
Principles and Practice of Medicine. Edinburgh, London, New York. 
 
http://etd.uwc.ac.za
 
 
86 
 
Hilaly, J., z.h. Israili and B.Lyoussi, 2004. Acute and chronic toxicological studies of Ajuga iva 
in experimental animals. J. Ethnopharmacol., 91:43-50. 
 
https://commons.wikimedia.org/wiki/File:Elytropappus_rhinocerotis_-_Renosterbos_-
_Cape_Town_2.jpg. 
 
http://www.plantzafrica.com/plantefg/elytrorhino.html. 
 
http://www.medicinenet.com/seizure/article. 
http://www.scidev.net/global/disease/feature/integrating-modern-and-traditional-medicine-facts-
and-figures.html. 
 
iHumans, Inc Website. (2001). Therapeutic aspects of Ginko Biloba extracts, flavonoids and 
Terpenoids constituents. 
http://ihumans.com/newscommentsarchive/Gingocompoundsactivity.html. 
 
 
Ikhiri K., Boubima D. and Kouloda D.D. (1992). Chemical screening of  medicinal plants used 
in the Traditional Pharmacopoeia of Niger. Int. J. Pharmacogn.,  30: 251-262.  
 
 
Iwu, M. M. (1993). Handbook of African medicinal plants. Boca Raton, CRC Press, pp. 1-5. 
 
Izzo, A.A. and Ernst, E., 2001. Interactions between herbal medicines and prescribed 
drugs. Drugs, 61(15), pp.2163-2175. 
 
http://etd.uwc.ac.za
 
 
87 
 
Jäger, A.K., Mohoto, S.P., van Heerden, F.R. and Viljoen, A.M., 2005. Activity of a traditional 
South African epilepsy remedy in the GABA-benzodiazepine receptor assay. Journal of 
ethnopharmacology, 96(3), pp.603-606. 
 
Jansen, M. and Dannhardt, G., 2003. Antagonists and agonists at the glycine site of the NMDA 
receptor for therapeutic interventions. European journal of medicinal chemistry, 38(7), pp.661-
670. 
 
Jordan, C.C. and Webster, R.A. eds., 1989. Neurotransmitters, drugs and disease. Blackwell. 
 
Kabatende, J., 2005. Pharmacological evaluation of some central nervous system effects of 
Cotyledon Orbiculata (Doctoral dissertation, University of the Western Cape). 
 
Kalant, H. and Roschlau, W.H.E., 1998. Principles of Med. Pharmacology. New York, NY: 
Oxford Univ Press. 
 
Katzung, G.B., Basic and Clinical Pharmacology. Antiepileptic Drugs. 
 
Kayprime Laboratory Consultants. (1992). HPLC in the Research Laboratory (Users Manual). 
2ND edition, Kayprime, Johannesburg, pp.8-22. 
 
http://etd.uwc.ac.za
 
 
88 
 
Keikelame, M.J., Hills, R.M., Naidu, C., de Sá, A. and Zweigenthal, V., 2012. General 
practitioners' perceptions on management of epilepsy in primary care settings in Cape Town, 
South Africa: An exploratory pilot study. Epilepsy & Behavior, 25(1), pp.105-109. 
Kirsch, J., 2006. Glycinergic transmission. Cell and tissue research, 326(2), pp.535-540. 
 
Klitgaard, H., Matagne, A. and Lamberty, Y., 2002. Use of epileptic animals for adverse effect 
testing. Epilepsy research, 50(1), pp.55-65. 
 
Lambert, J.R., Byrick, R.J. and Hammeke, M.D., 1981. Management of acute strychnine 
poisoning. Canadian Medical Association Journal, 124(10), p.1268. 
 
Laube, B., Maksay, G., Schemm, R. and Betz, H., 2002. Modulation of glycine receptor 
function: a novel approach for therapeutic intervention at inhibitory synapses?. Trends in 
pharmacological sciences, 23(11), pp.519-527. 
 
Lefevre, F. and Aronson, N., 2000. Ketogenic diet for the treatment of refractory epilepsy in 
children: a systematic review of efficacy. Pediatrics,105(4), pp.e46-e46. 
 
Leonard, B.E., 1997. Anxiolytics and the treatment of anxiety disorders.Fundamentals of 
Psychopharmacology, Third Edition, pp.211-239. 
 
Le Van Quyen, M., Martinerie, J., Navarro, V., Boon, P., D'Havé, M., Adam, C., Renault, B., 
Varela, F. and Baulac, M., 2001. Anticipation of epileptic seizures from standard EEG 
recordings. The Lancet, 357(9251), pp.183-188. 
http://etd.uwc.ac.za
 
 
89 
 
 
Lewis, W. H., & Elvin-Lewis, M. P. F. (2003). Medical botany: plants affecting human health. 
Hoboken, N.J., J. Wiley, pp .4-8; pp. 640-642. 
 
Li, T. S. C. (2002). Medicinal plants: culture, utilization and phytopharmacology. Boca Raton, 
Fla, CRC Press, pp.1-299. 
Loomis, T.A. and Hayes, A.W., 1996. Loomis's essentials of toxicology. academic press. pp. 
208-245. 
 
Lorke, D.,1983. A new approach to practical acute toxicity testing. Arch. Toxicol. 54: 275-287. 
 
Löscher, W., (2002a). Current status and future directions in the pharmacotherapy of epilepsy. 
Trends in pharmacological sciences. 23: 113-118. 
 
Löscher, W., (2002b). Animal models of epilepsy for the development of antiepileptogenic and 
disease-modifying drugs. A comparison of the pharmacology of kindling and post-status 
epilepticus models of temporal lobe epilepsy. Epilepsy research, 50(1), pp.105-123. 
 
 
Mafojane, N.A., Appleton, C.C., Krecek, R.C., Michael, L.M. and Willingham, A.L., 2003. The 
current status of neurocysticercosis in Eastern and Southern Africa. Acta tropica, 87(1), pp.25-
33. 
 
Marescaux, C., Vergnes, M., Liu, Z., Depaulis, A. and Bernasconi, R., 1991. GABAB receptor 
involvement in the control of genetic absence seizures in rats. Epilepsy research. Supplement, 9, 
pp.131-8. 
http://etd.uwc.ac.za
 
 
90 
 
 
Mauri, P. and Pietta, P., 2000. Electrospray characterization of selected medicinal plant 
extracts. Journal of Pharmaceutical and Biomedical Analysis,23(1), pp.61-68. 
 
Mayosi, B.M., Flisher, A.J., Lalloo, U.G., Sitas, F., Tollman, S.M. and Bradshaw, D., 2009. The 
burden of non-communicable diseases in South Africa. The Lancet, 374(9693), pp.934-947. 
 
McCabe, P.H., 2000. New anti-epileptic drugs for the 21st century. Expert opinion on 
pharmacotherapy, 1(4), pp.633-674. 
 
Morrow, J.I., Bingham, E., Craig, J.J. and Gray, W.J., 2000. Vagal nerve stimulation in patients 
with refractory epilepsy. Effect on seizure frequency, severity and quality of life. Seizure, 9(6), 
pp.442-445. 
 
Muhizi, T., 2002. The extraction, purification and evaluation of compounds from the leaves of 
Leonotis Leonorus for anticonvulsant activity (Doctoral dissertation, University of the Western 
Cape). 
Nicoll, R.A., 2001. Introduction to the pharmacology of CNS drugs. Lange Medical 
Books/McGraw-Hill, New York, USA, pp.351-363. 
 
O'shea, R.D., 2002. Roles and regulation of glutamate transporters in the central nervous 
system. Clinical and experimental pharmacology and physiology, 29(11), pp.1018-1023. 
 
http://etd.uwc.ac.za
 
 
91 
 
Ojewole, J.A.O., 2006. Antinociceptive, anti-inflammatory and antidiabetic properties of 
Hypoxis hemerocallidea Fisch and C.A Mey. (Hypoxidaceae) corm [‘african potato’] aqueous 
extract in mice and rats. J.Ethnopharmacol., 103:126-134. 
 
Poole, A. and Leslie, G.B., 1989. A practical approach to toxicological investigations. 
Cambridge University Press. pp. 2-117. 
 
 
Rabbani, M., Sajjadi, S.E. and Zarei, H.R., 2003. Anxiolytic effects of Stachys lavandulifolia 
Vahl on the elevated plus-maze model of anxiety in mice. Journal of Ethnopharmacology, 89(2), 
pp.271-276. 
 
Rang, H.P., Dale, M.M., Ritter, J.M., Flower, R.J. and Henderson, G., 2015.Rang and Dale 
farmacologia. Churchill Livingstone Elsevier. 
 
Reid, K.A., Jäger, A.K., Light, M.E., Mulholland, D.A. and Van Staden, J., 2005. Phytochemical 
and pharmacological screening of Sterculiaceae species and isolation of antibacterial 
compounds. Journal of ethnopharmacology, 97(2), pp.285-291. 
 
Risa, J., Risa, A., Adsersen, A., Gauguin, B., Stafford, G.I., van Staden, J. and Jäger, A.K., 2004. 
Screening of plants used in southern Africa for epilepsy and convulsions in the GABA A-
benzodiazepine receptor assay.Journal of Ethnopharmacology, 93(2), pp.177-182. 
 
Romanelli, P. and Anschel, D.J., 2006. Radiosurgery for epilepsy. The Lancet Neurology, 5(7), 
pp.613-620. 
 
http://etd.uwc.ac.za
 
 
92 
 
Schachter, S.C., 2009. Botanicals and Herbs: A Traditional Approach to Treating Epilepsy. 
Neurotherapeutics, 6(2), pp.415–420. Available at: http://dx.doi.org/10.1016/j.nurt.2008.12.004. 
 
Scheffer, I.E. and Berkovic, S.F., 2003. The genetics of human epilepsy.Trends in 
pharmacological sciences, 24(8), pp.428-433. 
 
Shetty, P., 2010. Integrating modern and traditional medicine: Facts and figures, Science and 
Development Network, 30 June 2010. Accessed November, 26, p.2011.  
Singh, D., Gawande, D.Y., Singh, T., Poroikov, V. and Goel, R.K., 2014. Revealing 
pharmacodynamics of medicinal plants using in silico approach: a case study with wet lab 
validation. Computers in biology and medicine, 47, pp.1-6. 
 
Sofowora, A. (1990). Medicinal plants and traditional medicine in Africa. New York, Wiley, pp. 
2-106. 
 
 
Spangenberg, J.J. and Lalkhen, N., 2006. Children with epilepsy and their families: Psychosocial 
issues. South African Family Practice, 48(6), pp.60-63. 
 
Stoltenow, C.L., Mostrom, M., Stoltenow, L.R. and Matz, T.E., 2002. Treatment of accidental 
strychnine poisoning in horses. Journal of Equine Veterinary Science, 22(11), pp.507-509. 
 
Sucher, N.J., 2006. Insights from molecular investigations of traditional Chinese herbal stroke 
medicines: Implications for neuroprotective epilepsy therapy. Epilepsy & Behavior, 8(2), pp.350-
362. 
http://etd.uwc.ac.za
 
 
93 
 
 
Tabuti, J.R.S., Dhillion, S.S. and Lye, K.A., 2003. Traditional medicine in Bulamogi county, 
Uganda: its practitioners, users and viability. Journal of Ethnopharmacology, 85(1), pp.119-129. 
Temkin, N.R., 2001. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: 
meta‐ analysis of controlled trials. Epilepsia, 42(4), pp.515-524. 
 
Thom, M.A.R.I.A., Sisodiya, S. and Najm, I., 2008. Neuropathology of epilepsy. Greenfield’s 
neuropathology. Arnold, London, pp.833-887. 
 
Thring, T.S. a & Weitz, F.M., 2006. Medicinal plant use in the Bredasdorp/Elim region of the 
Southern Overberg in the Western Cape Province of South Africa. Journal of 
Ethnopharmacology, 103, pp.261–275. 
 
Timbrell, J., 2001. Introduction to toxicology. CRC Press.pp.163-179. 
 
 
Tomlinson, T. R., and Akerele, O. (1998). Medicinal plants: their role in health and biodiversity. 
Philadelphia, University of Pennsylvania Press. 
 
Trist, D.G., 2000. Excitatory amino acid agonists and antagonists: pharmacology and therapeutic 
applications. Pharmaceutica Acta Helvetiae,74(2), pp.221-229. 
 
Tsang, S.Y. and Xue, H., 2004. Development of effective therapeutics targeting the GABAA 
receptor: naturally occurring alternatives. Current pharmaceutical design, 10(9), pp.1035-1044. 
http://etd.uwc.ac.za
 
 
94 
 
Tyagi, A. and Delanty, N., 2003. Herbal remedies, dietary supplements, and 
seizures. Epilepsia, 44(2), pp.228-235. 
 
Ulbricht, C. E., and Seamon, E. (2010). Natural Standard herbal pharmacotherapy: an evidence-
based approach. St. Louis, Mo, Mosby/Elsevier. 
 
Ure, J., Baudry, M. and Perassolo, M., 2006. Metabotropic glutamate receptors and 
epilepsy. Journal of the neurological sciences, 247(1), pp.1-9. 
 
Van Wyk, B.-E., Van  Oudtshoorn, B.,and Gericke, N. (2000). Medicinal plants of South Africa. 
Pretoria, Briza Publications. 
 
Velluci, S.V. and Webster, R.A. 1984. Antagonism of caffeine-induced seizures in mice by Ro 
15-1788. Eur.J.Pharmacol. 97:289-293. 
 
Vickery, M.L. and Vickey, B., 1979. Plant products of tropical Africa. Macmillan. 
 
Williamson, E.M., Okpako, D.T. and Evans, F.J., 1996. Pharmacological methods in 
phytotherapy research: volume 1: Selection, preparation and pharmacological evaluation of 
plant material. John Wiley & Sons Ltd. 
 
World Health Organization, 2002. WHO traditional medicine strategy 2002-2005. 
 
http://etd.uwc.ac.za
 
 
95 
 
World Health Organization, 2005. National policy on traditional medicine and regulation of 
herbal medicines: Report of a WHO global survey. 
 
World Health Organization (WHO), 2015. WHO traditional medicine strategy 2014–2023. 
2013. Geneva: World Health Organization. 
 
Wood, D.M., Webster, E., Martinez, D., Dargan, P.I. and Jones, A.L., 2002. Case report: 
Survival after deliberate strychnine self-poisoning, with toxicokinetic data. Critical Care, 6(5), 
p.1. 
 
Zeman, A., Kapur, N. and Jones-Gotman, M., 2012. Epilepsy and memory. Oxford University 
Press. 
 
Ziemann, U., Tergau, F., Wischer, S., Hildebrandt, J. and Paulus, W., 1998. Pharmacological 
control of facilitatory I-wave interaction in the human motor cortex. A paired transcranial 
magnetic stimulation study.Electroencephalography and Clinical 
Neurophysiology/Electromyography and Motor Control, 109(4), pp.321-330. 
 
Zollman, C. and Vickers, A., 1999. ABC of complementary medicine: What is complementary 
medicine?. British Medical Journal, 319(7211), p.693. 
 
 
 
